

# A country-based review in COVID-19 related research developments

Nikunja Mohan Modak  
Palpara Vidyamandir, Chakdaha-741222, West Bengal, India  
[Email-nikunja.modak@gmail.com](mailto:Email-nikunja.modak@gmail.com)

Sudipta Sinha  
Department of Mathematics, Burdwan Raj College, University of Burdwan,  
West Bengal, India, Pin-713104  
[Email-sudipta.sinha08@gmail.com](mailto:Email-sudipta.sinha08@gmail.com)

Shib Sankar Sana  
<sup>2</sup>Department of Mathematics,  
Kishore Bharati Bhagini Nivedita College  
Ramkrishna Sarani, Behala, Kolkata-700060, India.  
Email: [shib\\_sankar@yahoo.com](mailto:shib_sankar@yahoo.com)

## Abstract:

The COVID-19 pandemic has turned our life topsy-turvy. It has brought a massive change in all sectors around the world. A great number of research papers have already been published accounting for various aspects of the COVID-19 issue, owing to the ever-increasing interest in this hot area. The essential data is gathered using the well-known and dependable search engine SCOPUS. We looked at research papers, journals, and reviews from 25 leading countries to highlight a comprehensive study of research output through COVID-19 papers. This study focuses on the top authors, leading articles, and journals from various nations, the percentage of published papers in various fields, and the top collaborative research work from different authors and countries. USA, U.K., China, Italy, and India have all made a significant contribution to COVID-19 research. The USA is the leading country followed by U.K. and China but for H-index China is in the best position. The highest number of papers has been developed in the area of 'medicine'. The Harvard Medical School of the U.K. contributed the highest number of papers followed by the University of Toronto of Canada. Professor K Dhama of India has published the highest number of papers while C. Huang of China received the highest number of citations. It also highlights that several authors have differing opinions on the efficacy of taking the medicine remdesivir. Our research provides a complete and comprehensive image of the virus's current research status, or in other words, a roadmap of the present research status.

**Keywords:** *COVID-19; Pandemic; Research; Review; Country Analysis; Scopus*

## **1. Introduction:**

The world is in disarray today as a result of the coronavirus's sudden attack. In December 2019, an epidemic of this lethal virus was reported in China's Wuhan city of Hubei Province. The virus spread fast over the world as a result of developed international communication. At the time of the virus's initial outbreak, countries like the United States of America (USA), Italy, France, Brazil, and the United Kingdom (U.K.) are in upheaval. Since its beginning in 2019, WHO recognized the fatal virus as COVID-19. This virus is most commonly referred to as coronavirus because of its crown-like structure. The virus poses a global health emergency throughout the world. To begin, practically most of the countries on Earth are being forced to go into lockdown day after someday to fight this lethal virus, as physicians or scientists are at a loss for how to combat it. Individuals are directed/asked to remain in their homes. The first wave of coronavirus killed a large number of people, including doctors, police officers, health care personnel, and teachers, as well as many ordinary citizens. This funeral procession was watched by the entire world. The coronavirus has a profound effect on social life and the environment. The world economy suffered tremendous damage as a result of the prolonged shutdown. Numerous businesses have ceased operations. The mode of transportation must be halted. As a result, a large number of people lose their work and become jobless. Many are compelled to switch jobs in order to survive. Work from home is a trend that began in the industry, information technology, education, and other sectors. So, researches have been started towards various sides like socio-economic, environment along with the discovery of medicine.

There are several bibliometric studies on COVID-19 publications. To the best of our knowledge, our study is the first one focusing on the contemporary COVID-19 literature depicting a comprehensive global research scenario. We have developed a country-wise review analysis of the current research status that emerged due to the sudden appearance of COVID-19. Su et al. (2021) presented a detailed and comprehensive bibliometric study providing research output of

various institutions, countries, scientists or physicians, etc. The objective of their study is to analyze the most cited papers as well as to find the research trend, and provide necessary information to the people. They reviewed 51047 papers, and in this matter, they rely on the Web of Science. According to their observation, The British Medical Journal is in a leading position in terms of publication but in terms of citations, The Lancet and New England Journal of Medicine is in the focus, and are in a better position. By the bibliometric study, Kappi et.al. (2021) would like to seek the research priorities highlighting top-cited publications, top-ranking institutes, top-contributing countries, top-publishing, top-citing, and top H-indexing journals, top-sub disciplines, top-language of research, etc., and so many aspects. They considered a total of 17333 different types of published articles from the web of science. According to their study, The British Medical Journal ranks first contributing 663 papers (3.87 % of the total publication) followed by the Journal of Medical Virology with 325 publications. The famous journal New England Journal of Medicine received the highest number of citations amounting to 5881 followed by The Lancet with 4780 citations and the Journal of American Medical Association (JAMA) has a total of 4634 citations. But in the light of the H-index JAMA occupies the second position with a 29 h-index and the journals New England Journal of Medicine and The Lancet have an h-index of 32 and 26 respectively. Keyword 'COVID-19' is mostly used with a total of 6180 in number followed by SARS-Cov-2 having 1926 times. The keyword 'coronavirus' appears 1570 times. The bibliometric study of Vasantha Raju et al. (2020) reflects that India is also playing an impressive role to enhance the progress of research on COVID-19. The authors framed their study based on the published papers on SARS-COV-2 using the WHO database as the data source. They observed that most of the researchers belong to either AIIMS or ICMR institutes. Indian Journal of Medical Research (IJMR) published a total of 14 papers within the time under consideration which is the highest in number. Epidemiology is the main focus of research. The keyword 'COVID' appeared 34 times followed by 'coronavirus' which occurs 23 times. Hossain (2020) presented a bibliometric analysis focusing on the application of artificial intelligence (AI) in COVID-19 research. They rely on the extensive data source 'MEDILINE' and considered 105 articles in this context. The primary purpose of AI is to promote equity. So, they try to find out the disparity in health, socio-legal issues, progress of vaccines, and practical public health research on COVID-19. According to their observation, there is tough competition between the USA and China concerning the publication of papers contributing 24, and 23 papers

respectively. Through a systematic review and meta-analysis, Rodriguez –Morales et al., (2020) attempted to offer an overview of clinical trials. They looked at more than 780 patients to observe risk factors like comorbidity, Intensive Care Unit (ICU) requirements, etc. They estimate that at least one-fifth of the admitted patients need ICU which is nearly impossible to provide for most countries. They considered the period between 01/01/2020-23/02/2020. Based on 172 studies, Chu et al. (2020) produced a systematic meta-analysis through which they examined the risk factors for the spread of COVID-19 infections. They observed that a 2-meter distance is optimum to mitigate the risk factor of infection. They also see that N-95 is more effective than the other masks. Wiersinga et al. (2000) developed a review that focuses on symptoms of infected patients, duration of exposure, the right time of diagnosis, and treatment among other things. They observed that 75% of hospitalized patients need oxygen support. They notice that remdesivir reduces the time it takes for patients who are discharged without oxygen. They emphasized the use of masks, maintaining social distancing, and tracing contacts. Ghadir et al. (2022) identified seventy different risks in a supply chain under seven categories due to the outbreak of COVID-19. Mondal & Roy (2021) developed supply chain models to retain supply among production centers and hospitals during the COVID-19 pandemic situation. Tirkolaee et al. (2022) presented a multi-period multi-echelon multi-product supply chain network of face masks during the COVID-19-pandemic. They used Multi-Objective Grey Wolf Optimization Algorithm and Non-Dominated Sorting Genetic Algorithm II to solve the proposed model and to find Pareto optimal solutions. Khalilpourazari et al. (2021) used a Gradient-based Grey Wolf Optimizer for modeling and prediction of the COVID-19 pandemic. AYDIN and Tirkolaee (2022) analyzed country-level growth dynamics of COVID-19. Babae et al. (2021) presented a sustainable medical waste management policy under the COVID-19 pandemic situation.

In this paper, we present a bibliometric study on different aspects of COVID-19 which can highlight a complete picture of research status or progress on COVID-19. Health emergencies are going on all over the world due to the sudden occurrence of coronavirus, so there is a consensus on the progress of research on drugs or vaccines. By this study, it is possible to know which country is at which stage of research. Such type of study also analyses the effect on the social, economic, psychological, environmental, information technology, and industrial sectors. Though the medicinal field is in the leading position in terms of publication of covid related papers, other fields are also not far behind in this regard.

Scopus database is used for the collection of papers/articles as Scopus is a very well-known reliable source and contains a large dataset. The purpose of the present study is to explore the current research status of the deadly virus COVID-19. By this study, we have tried to comprehend which key realizations have been achieved to fight against the fatal virus. By this paper, we intend to highlight: (i) which countries are the leader in COVID-19 research? (ii) which author has published the highest number of papers? (iii) which authors have received a very good number of citations? (iv) how far research has been advanced in discovering fruitful medicine or vaccine around the world? (v) which institute has put special emphasis on research of COVID-19? (vi) which measures might be taken by the common people to save themselves from infection of the fatal virus? Here we have considered the papers based on the number of citations. Naturally, papers published in early 2020 have received more citations than the recently published papers. During that period there are no available medicines or vaccines in the world. Thus, the consciousness and carefulness of the people were very important at that stage. (vii) how much this calamitous situation has globally impacted other sectors like socio-economic, education, business, environment, etc. (viii) is there any sector which is not covered by the research that means is there any gap in research? (ix) is there any mediator for escalating/accelerating the infection? (x) since most of the papers considered here included clinical trials, real case studies of confirmed infected patients of different hospitals separately considering male and female, the study can delineate which sex are mostly infected by the COVID-19 or what steps may be adapted after recovery from the disease?.

The rest of the paper is arranged as follows: Section 2 discusses the methodology. Section 3 discusses Mathematical expressions and corresponding graphical representation of Covid-19 infections in the top six countries. The result as well as the necessary discussion is provided in Section 4. Major findings are presented in Section 5. Finally, a comprehensive conclusion is presented in Section 6.

## **2. Methods:**

The well-known database SCOPUS is used to collect data for this study. It is a universally accepted and consistent database for scientific publications. SCOPUS covers 22,794 active titles and 13,583 inactive titles in its database. When searching for documents that had used “COVID-19” in the title or abstract or keywords, SCOPUS’ search engine revealed a total of 207854 documents up to 14th October 2021. We limit the search result to English language and Journal publications. Next, we limit the search result to document types “article”, and “review”. In this way, we arrived at a total of 143686 documents (122465 articles, and 21221 reviews) for this study. Details of the article selection procedure are given in the Figure 1. A document will be considered for a country if one or more authors used affiliation of that country. Suppose a document has N authors from M different countries then it will be considered in the account of all M countries associated with its authors. Thus, a document may be possible to display in the account of more than one country. Based on the final data set of 143686 documents we find the leading twenty-five productive countries in COVID-19 research.




Figure 1. Document Selection Procedure.

Country-wise collected data are arranged and classified based on different indicators like the total number of publications (TP), H-index, and citation thresholds for 50, 100, 200, 500, and 1000 citations. A country has X number of publications and we have arranged contributing authors, institutions, and keywords based on those X publications. Thus, it may be possible that an author/institution can lead in a profile for a different country if it has strong collaboration with authors/institutions of that country. In this study, we also highlight frequently used keywords for the leading countries to explore research directions on COVID-19-related issues.

### **3. Mathematical expressions and corresponding graphical representation of Covid-19 infections in the top six countries**

More than 230 countries in the world have more or less been affected by the calamitous virus. According to the worldometer as of 30th June, 2021 more than 182 million people are infected and the death toll is more than 3.9 million. The countries USA, India, Brazil, France, Russia, and Turkey secure the first six ranks from the top. The countries the USA, Brazil France had been attacked all of a sudden in the midway of February 2020.

#### **Graphical Representation of number of infections of top six countries**




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7



We have fitted the infected curve with three trend lines (straight lines) in the case of the USA (see Figure 2). The equations of the trend lines are

$$y = 25698x - 2000000; y = (1000000)x - 40000000; \text{ and } y = 33008x + 10000000.$$

It is observed that between 40 to 58 weeks (04/11/2020 to 05/03/2021) the gradient of the straight lines is nearly four times the same between 9 to 40 weeks (11/04/2020 to 28/10/2020) in the case of the USA. In India, five straight lines (see Figure 3) are needed to capture the graph of the number of infections. The equations of the trend lines are shown in Figure 2. We observe that in India, between 62 and 70 weeks (02/04/2021 to 26/05/2021) the trend line is steeper than the others. That means the number of infections rapidly increases in this time interval. The number of infections in Brazil has been fitted by three-line segments (see Figure 4), which are

$$y = 9982x - 40255, \quad y = 21869x - 3000000 \text{ and } y = 42831x - 10000000$$

The values of  $R^2$  are 0.650, 0.995, and 0.998, which implies the goodness of fit. Here we observe that between the time interval of 12 weeks to 50 weeks (02/05/2020 to 08/01/2021) the slope of the trend line is more than two times the slope before 12 weeks (That is, before 02/05/2020) and after 50 weeks (That is, after 08/01/2021) it almost doubled, which implies the number of infected cases increasing severely with time in Brazil. In France, the curve describing the number of infections needs six-line segments to capture it well (see Figure 5). The straight lines are  $y = 7545x - 441$ ,  $y = 25564x - 3000000$ ,  $y = 64032x - 2000000$ ,  $y = 16856x - 6000000$ ,  $y = 28948x + 4000000$  and  $y = 10951x - 3000000$  respectively. From these equations, we notice that there exist some ups and downs in the slopes of the straight lines. Between 30 to 41 weeks (26/08/2020 to 11/11/2020) the gradient of the trend lines is very high, which indicates that in this time interval the number of infected cases boosted up. In the case of Russia, the infected curve is well fitted by four straight lines as shown in Figure 6, which are given by  $y = 2750x - 9452$ ,  $y = 16074x - 5000000$ ,  $y = 65833x + 46190$  and  $y = 44988x - 35118$ . The values of the slopes (That is, 2750, 16074, 65833, 44988) indicate the ups and downs in the graph of the number of infections. In Turkey, the equations of the seven trend lines, which are needed to fit the infected graph, (see Figure 7) are  $y = 6716x - 19243$ ,  $y = 29602x - 10000000$ ,  $y = 24512x + 23905$ ,  $y = 67939x - 1000000$ ,  $y = 48902x + 2000000$ ,  $y = 69766x - 48518$  and  $y = 16728x - 6000000$ . Here also a variation in the

values of the slope of the trend lines are noticed, which shows that the increment of infected cases also varies in different time slots. The values of  $R^2$  are 0.513, 0.972, 0.974, 0.961, 0.983, 0.989, and 0.971.

#### 4. Research Outcomes


In Table 1 we consider top 25 productive countries based on TP in COVID-19 related research. Ranking is given based on the TP.

**Table 1.** Leading countries in COVID-19 research development.

| Rank | Country        | TP    | H-index | Citation Threshold |            |            |            |           |
|------|----------------|-------|---------|--------------------|------------|------------|------------|-----------|
|      |                |       |         | $\geq 1000$        | $\geq 500$ | $\geq 200$ | $\geq 100$ | $\geq 50$ |
| 1    | United States  | 38939 | 272     | 34                 | 108        | 402        | 914        | 1930      |
| 2    | United Kingdom | 15117 | 186     | 23                 | 54         | 169        | 385        | 815       |
| 3    | China          | 14654 | 279     | 57                 | 145        | 384        | 724        | 1210      |
| 4    | Italy          | 11476 | 153     | 6                  | 28         | 111        | 288        | 674       |
| 5    | India          | 10726 | 95      | 3                  | 9          | 31         | 88         | 249       |
| 6    | Canada         | 6516  | 122     | 7                  | 21         | 66         | 156        | 324       |
| 7    | Spain          | 6421  | 105     | 4                  | 15         | 45         | 111        | 270       |
| 8    | Germany        | 5965  | 132     | 10                 | 28         | 87         | 178        | 358       |
| 9    | Australia      | 5881  | 115     | 7                  | 18         | 48         | 140        | 285       |
| 10   | France         | 4811  | 118     | 6                  | 23         | 68         | 142        | 306       |
| 11   | Brazil         | 4699  | 76      | 3                  | 10         | 23         | 59         | 132       |
| 12   | Turkey         | 3883  | 62      | 1                  | 4          | 10         | 34         | 89        |
| 13   | Iran           | 3790  | 75      | 0                  | 5          | 14         | 50         | 134       |
| 14   | Saudi Arabia   | 3279  | 64      | 1                  | 5          | 19         | 36         | 88        |
| 15   | Japan          | 2903  | 75      | 5                  | 13         | 26         | 58         | 103       |
| 16   | Netherlands    | 2880  | 102     | 5                  | 19         | 54         | 106        | 201       |
| 17   | Switzerland    | 2669  | 97      | 4                  | 11         | 41         | 92         | 193       |
| 18   | South Korea    | 2527  | 76      | 1                  | 6          | 24         | 61         | 109       |
| 19   | Pakistan       | 2097  | 53      | 0                  | 2          | 8          | 21         | 58        |
| 20   | South Africa   | 2085  | 55      | 1                  | 4          | 7          | 29         | 64        |
| 21   | Poland         | 2063  | 55      | 1                  | 3          | 7          | 20         | 63        |
| 22   | Indonesia      | 1924  | 40      | 1                  | 1          | 6          | 12         | 24        |
| 23   | Egypt          | 1907  | 51      | 0                  | 3          | 10         | 22         | 54        |
| 24   | Belgium        | 1848  | 78      | 2                  | 6          | 23         | 55         | 127       |
| 25   | Sweden         | 1797  | 71      | 2                  | 10         | 19         | 42         | 102       |


Table 1 includes 25 countries in terms of the TP on the current burning topic COVID-19. The Table 1 will help to overview the research scenario at a glance. Among twenty-five countries, eleven belong to Europe (UK, Italy, Spain, Germany, France, Turkey, Netherlands, Switzerland, Poland, Belgium, and Sweden); two in North America (the USA, and Canada); Brazil in South America; eight in Asia (China, India, Pakistan, Iran, Saudi Arabia, Japan, Indonesia, and South Korea); Australia in Oceania, and two are in Africa (South Africa, and Egypt). The USA comfortably is in the leading position having published 38939 research papers/articles within a short time. The U.K. occupies the second position in terms of TP with 15117 publications. But there is a significant difference/gap between the USA and the UK in terms of TP. In terms of the H-index, China secures 1st position having a value of 279 whereas the USA bears 272 H-index values. UK has consistency in terms of TP and H-index values. If we look at the citation threshold value, we notice that China retains a better position than the USA. Fifty-seven (57) papers have crossed the milestone of 1000 citations whereas in the USA only 34 papers have reached the milestone. There are ten countries in Table 1 which have at least five papers having more than 1000 citations.

Iran, Pakistan, and, Egypt has no papers over the threshold of 1000 citations but these countries respectively have five, two, and three papers over the threshold of 500 citations. According to the 200, 100, and 50 citation thresholds, the USA is in the leading position within the Table 1. Though Indonesia is at the twenty-second position in the Table 1 of the top 25 countries in respect of TP, it has the least H-index (40). All other countries in Table 1 except Indonesia have an h-index value of more than fifty. Figure 8 presents the top ten countries according to the h-index.



**Figure 8.** Top ten countries according to h-index

Figure 9 presents the top ten countries according to number of papers more than the threshold of 100 citations.



**Figure 9.** Top ten countries according to number of papers more than 100 citations

Almost all countries around the world are strongly involved in Covid-19 related research. In order to identify the leading ones, let us look into the results according to some well-known bibliometric indicators. Table 1 presents the 25 most productive countries in this field. In Table 2 we prepared a ranking of the top 20 countries by their research performance. Research Score ( $R_s$ ) is calculated based on the indicators TP, H-index, and threshold of 50 citations (T50-index) using formula

$$R_s = \frac{\log(TP_i + 1)}{\max \log(TP + 1)} + \frac{\log(H_i + 1)}{\max \log(H + 1)} + \frac{\log(T50_i + 1)}{\max \log(T50 + 1)}$$

Table 2. Top 20 countries based their performance in covid-19 related research

| Rank | Name of the Country | Research Score ( $R_s$ ) |
|------|---------------------|--------------------------|
| 1    | United States       | 2.995507                 |
| 2    | China               | 2.845873                 |
| 3    | United Kingdom      | 2.724994                 |
| 4    | Italy               | 2.639395                 |
| 5    | Germany             | 2.468024                 |
| 6    | Canada              | 2.449359                 |
| 7    | India               | 2.417847                 |
| 8    | Australia           | 2.412365                 |
| 9    | France              | 2.407266                 |
| 10   | Spain               | 2.397555                 |
| 11   | Netherlands         | 2.277783                 |
| 12   | Switzerland         | 2.256415                 |
| 13   | Brazil              | 2.217219                 |
| 14   | Iran                | 2.196537                 |
| 15   | Japan               | 2.136838                 |
| 16   | South Korea         | 2.133453                 |
| 17   | Belgium             | 2.128442                 |
| 18   | Turkey              | 2.111945                 |
| 19   | Saudi Arabia        | 2.100024                 |
| 20   | Sweden              | 2.080609                 |

Now look at the spearman's rho correlation coefficient to examine correlation among the different rankings based on publications, H-index, T50 index, and our combined index. We considered ranking of top 10 countries of Table 2 under different the bibliometric measures to determine the spearman's rho correlation coefficient and results are presented in Table 3.

Table 3. The spearman's rho correlation coefficient under different the bibliometric measures

| Indexes | Combined | Combined | Combined | TP | TP | T50 |
|---------|----------|----------|----------|----|----|-----|
|---------|----------|----------|----------|----|----|-----|

|  | <b>&amp;<br/>TP</b>          | <b>&amp;<br/>H</b>           | <b>&amp;<br/>T50</b>         | <b>&amp;<br/>H</b>         | <b>&amp;<br/>T50</b>       | <b>&amp;<br/>H</b>           |
|--|------------------------------|------------------------------|------------------------------|----------------------------|----------------------------|------------------------------|
| spearman's rho correlation coefficient | $\frac{139}{165}$<br>= 0.842 | $\frac{149}{165}$<br>= 0.903 | $\frac{151}{165}$<br>= 0.915 | $\frac{37}{55}$<br>= 0.673 | $\frac{23}{33}$<br>= 0.697 | $\frac{163}{165}$<br>= 0.988 |

From Table 3, one may note that our combined index is positively correlated with all the three indexes TP, H index, and T50. Ranking of the universities under the total publication and H-index are negatively correlated while total citation and H-index are almost perfectly correlated. Upcoming Subsections (4.1 to 4.11) discuss the contribution of each of the leading countries separately in terms of leading topics, subject areas, authors, and institutions. Moreover, it explores leading articles of these countries and reviews the impact of those articles.

#### 4.1 USA

Subsection 4.1 presents contribution of USA in COVID-19 related research. Table 4 shed light on the top twenty-five authors, subject area, and institution of the USA in terms of TP.

**Table 4.** Leading authors, institutions, subject areas, and keywords in COVID-19 research in USA

| <b>R</b> | <b>Authors</b>       | <b>TP</b> | <b>Subject area</b>                          | <b>TP</b> | <b>Institution</b>                      | <b>TP</b> |
|----------|----------------------|-----------|--|-----------|---|-----------|
| 1        | Lippi, G.            | 63        | Medicine                                     | 24635     | Harvard Medical School                  | 2140      |
| 2        | Krammer, F.          | 58        | Social Sciences                              | 5986      | Massachusetts General Hospital          | 1061      |
| 3        | Baric, R.S.          | 52        | Biochemistry, Genetics and Molecular Biology | 4264      | Icahn School of Medicine at Mount Sinai | 953       |
| 4        | Henry, B.M.          | 48        | Immunology and Microbiology                  | 2843      | Brigham and Women's Hospital            | 916       |
| 5        | Alter, G.            | 38        | Psychology                                   | 2345      | University of Washington                | 908       |
| 6        | Amanat, F.           | 38        | Nursing                                      | 2286      | University of California, San Francisco | 885       |
| 7        | Greninger, A.L.      | 37        | Environmental Science                        | 1881      | University of Pennsylvania              | 844       |
| 8        | Al-Tawfiq, J.A.      | 36        | Multidisciplinary                            | 1608      | University of Michigan, Ann Arbor       | 742       |
| 9        | Diamond, M.S.        | 33        | Pharmacology, Toxicology and Pharmaceutics   | 1388      | Stanford University                     | 716       |
| 10       | Gholamrezanezhad, A. | 33        | Health Professions                           | 1308      | Johns Hopkins University                | 660       |
| 11       | Jerome, K.R.         | 33        | Business, Management and Accounting          | 1279      | Yale School of Medicine                 | 650       |
| 12       | Shi, P.Y.            | 33        | Neuroscience                                 | 1261      | University of California, Los Angeles   | 647       |
| 13       | Brodie, D.           | 31        | Computer Science                             | 1238      | Columbia University                     | 627       |
| 14       | Memish, Z.A.         | 31        | Engineering                                  | 1159      | Weill Cornell Medicine                  | 622       |

|    |                   |    |                                      |      |  |     |
|----|-------------------|----|--------------------------------------|------|--|-----|
| 15 | Menachery, V.D.   | 31 | Agricultural and Biological Sciences | 1012 | Mayo Clinic  | 613 |
| 16 | Chowell, G.       | 30 | Economics, Econometrics and Finance  | 993  | University of California, San Diego                    | 610 |
| 17 | García-Sastre, A. | 30 | Arts and Humanities                  | 985  | The University of North Carolina at Chapel Hill        | 606 |
| 18 | Hall, A.J.        | 30 | Chemistry                            | 887  | Stanford University School of Medicine                 | 606 |
| 19 | Latkin, C.A.      | 30 | Mathematics                          | 585  | Johns Hopkins School of Medicine                       | 604 |
| 20 | McCullough, P.A.  | 29 | Physics and Astronomy                | 566  | National Institutes of Health NIH                      | 602 |
| 21 | Sette, A.         | 29 | Chemical Engineering                 | 457  | Harvard T.H. Chan School of Public Health              | 601 |
| 22 | Casadevall, A.    | 28 | Materials Science                    | 423  | Johns Hopkins Bloomberg School of Public Health        | 598 |
| 23 | Pinsky, B.A.      | 28 | Decision Sciences                    | 282  | University of Pennsylvania Perelman School of Medicine | 582 |
| 24 | Barouch, D.H.     | 27 | Energy                               | 263  | Yale University  | 546 |
| 25 | Lipsitch, M.      | 27 | Earth and Planetary Sciences         | 257  | University of Toronto                                  | 539 |

Professor Lippi, G possesses the highest position in the list of leading authors with 63 publications. Professor F. Krammer and Professor R.S. Baric respectively are the second and third-ranked authors for the USA in COVID-19 research. It is also seen that most of the published papers belong to the field /area of medicine which is very obvious because researchers are actively engaged in the discovery of effective medicine or vaccine to save from the grip of the fatal virus. The USA is the worst affected country in the world and so the USA reinforced to prepare the vaccine or medicine for immediate remedy. Thus, the subject area of medicine has gained utmost priority and immediate urgency. Subject areas ‘Social Sciences’ and ‘Biochemistry, Genetics and Molecular Biology’ are respectively the second and third leading research areas in the USA for COVID-19 research. Harvard Medical School has the highest number of publications with a total of 2140 publications followed by Massachusetts General Hospital, which has 1061 publications in COVID-19 research. Table 5 presents information for the top ten most-cited COVID-19-related articles written by authors from the USA.

**Table 5.** List of leading articles of USA

| R | Title  | Authors  | Journal  | Citation |
|---|--|--|--|----------|
| 1 | Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area | Richardson S., Hirsch J.S., Narasimhan M., et al. (2020) | JAMA - Journal of the American Medical Association | 3476     |
| 2 | First case of 2019 novel coronavirus in the  | Holshue M.L., DeBolt C.,                                 | New England Journal                                | 2863     |

|    |   |   |                                 |      |
|----|---|---|---------------------------------|------|
|    | United States   | Lindquist S., et al. (2020)                             | of Medicine                     |      |
| 3  | A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19  | Cao B., Wang Y., Wen D., Liu W., et al. (2020)          | New England Journal of Medicine | 2668 |
| 4  | Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China                                  | Mao L., Jin H., Wang M., et al., (2020)                 | JAMA Neurology                  | 2655 |
| 5  | The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: Estimation and application   | Lauer S.A., Grantz K.H., Bi Q., et al., (2020)          | Annals of Internal Medicine     | 2208 |
| 6  | Remdesivir for the treatment of COVID-19 — Final report   | Beigel J.H., Tomashek K.M., Dodd L.E., et al., (2020)   | New England Journal of Medicine | 2186 |
| 7  | Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine   | Polack F.P., Thomas S.J., Kitchin N., et al., (2020)    | New England Journal of Medicine | 2180 |
| 8  | Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus | Wan Y., Shang J., Graham R., Baric R.S., Li F. (2020)   | Journal of Virology             | 1953 |
| 9  | The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak  | Rothan H.A., Byrareddy S.N. (2020)                      | Journal of Autoimmunity         | 1910 |
| 10 | Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19  | Ackermann M., Verleden S.E., Kuehnel M., et al., (2020) | New England Journal of Medicine | 1810 |

Richardson et al. (2020) examined the characteristics, comorbidities, and, outcomes of the 5700 patients admitted to hospitals in New York City with the symptom of COVID-19. The number of citations (3476) ensures the quality of the paper. Holshue et al. (2020) discussed the first case of coronavirus in the USA. The paper has been published in the well-reputed New England Journal of Medicine. A clinical trial of different drugs started in war-time activities. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19 has been noted by Cao et al. (2020). It is supposed that the drugs lopinavir and ritonavir may be effective to fight against the deadly virus. This paper is also included in the list of leading articles in the U.K. and, China. The paper has also a good number of citations. The effect of the fatal coronavirus was so horrible that the whole world was keenly waiting for the preventive vaccine. So, the paper reinforcing the clinical trials of lopinavir-ritonavir has received major attention from researchers. Beigel et al. (2020) also submitted a report about the use of the much-discussed drug Remdesivir. Mao et al. (2020) pointed out the neurologic manifestations. They think that different aspects of neurologic manifestations are yet to be explored. They studied patients admitted for one month (16th January 2020 to 19th February 2020) to the Huazhong University of Science and Technology in Wuhan of China to reach their conclusion. Mao et al. (2020) also belongs to the list of authors in China. Ackermann et al. (2020) compared two types of lungs of seven expired patients – one



from COVID-19 virus and the other from acute respiratory distress syndrome and observed that there exist severe endothelial injury and angiocentric inflammation in the lungs of dead patients from the COVID-19 virus. Wan et al. (2020) studied the structure of coronavirus (2019n-CoV) that emerged from the Wuhan province of China based on the prior knowledge of SARS-CoV-2. They concluded that 2019n-CoV-2 uses Angiotensin-Converting Enzyme-2 (ACE2) as its host receptor and may be severe to humans due to its mutant nature. Rothan et al. (2020) focused on the symptoms of patients, way of transmission, and pathogens and emphasizes finding out the way to prevention of the virus. Out of the ten leading papers five (05) have been published in the famous journal New England Journal of Medicine. So, we can state that researchers frequently choose this journal for the publication of their papers.

#### 4.2. United Kingdom

Subsection 4.2 presents contribution of United Kingdom (UK) in COVID-19 related research. Table 6 presents the top fifteen authors, subject area, and institution of the UK in terms of TP.

**Table 6.** Leading authors, subject areas, and institutions in COVID-19 research in UK

| R  | Authors         | TP | Subject area                                 | TP   | Institution                                    | TP   |
|----|-----------------|----|--|------|--|------|
| 1  | Smith, L.       | 57 | Medicine                                     | 9237 | University of Oxford                           | 1414 |
| 2  | Zumla, A.       | 54 | Social Sciences                              | 2401 | University College London                      | 1267 |
| 3  | Eggo, R.M.      | 52 | Biochemistry, Genetics and Molecular Biology | 1561 | Imperial College London                        | 1149 |
| 4  | Griffiths, M.D. | 51 | Immunology and Microbiology                  | 957  | King's College London                          | 943  |
| 5  | Khunti, K.      | 51 | Psychology                                   | 862  | University of Cambridge                        | 725  |
| 6  | Zambon, M.      | 46 | Environmental Science                        | 820  | London School of Hygiene & Tropical Medicine   | 685  |
| 7  | Funk, S.        | 45 | Nursing                                      | 762  | The University of Manchester                   | 583  |
| 8  | Hopkins, C.     | 45 | Business, Management and Accounting          | 738  | University of Oxford Medical Sciences Division | 575  |
| 9  | Jit, M.         | 45 | Multidisciplinary                            | 529  | The University of Edinburgh                    | 567  |
| 10 | Abbott, S.      | 41 | Engineering                                  | 511  | University of Liverpool                        | 526  |
| 11 | Harky, A.       | 41 | Arts and Humanities                          | 503  | University of Birmingham                       | 461  |
| 12 | Klenerman, P.   | 40 | Computer Science                             | 487  | University of Bristol                          | 354  |
| 13 | Jarvis, C.I.    | 39 | Neuroscience                                 | 482  | University of Glasgow                          | 348  |
| 14 | Edmunds, W.J.   | 38 | Economics, Econometrics and Finance          | 474  | Nuffield Department of Medicine                | 347  |
| 15 | Kucharski, A.J. | 37 | Pharmacology, Toxicology and Pharmaceutics   | 452  | Public Health England                          | 346  |

Professor L. Smith has 57 publications securing the top position in Table 6 followed by Professor A. Zumla and Professor R.M. Eggo. The top five authors have more than fifty publications in COVID-19 related research. The world-famous institute the University of Oxford occupies first place with 1414 publications. The University College London and Imperial College London respectively have 1267 and 1149 publications in COVID-19 research and are in the second and third position in the list of the leading institution in the UK. An interesting observation is that the Table 6 contains mostly the university name which ensures the excellent performance of the universities in the UK in advancing the research on COVID-19. It is earlier mentioned that the subject ‘medicine’ is the highest priority, and focuses on this emergent situation. So, the medicinal sector has the most publication bearing the number 9237. Note that, leading subject areas in COVID-19 research are quite similar to the USA. Table 7 presents information for the top ten most-cited COVID-19 related articles written by authors from the UK.

**Table 7. List of leading articles in U.K.**

| <b>R</b> | <b>Title</b>   | <b>Authors</b>  | <b>Journal</b>                   | <b>Citation</b> |
|----------|--|---|----------------------------------|-----------------|
| 1        | Virological assessment of hospitalized patients with COVID-2019  | Wölfel R., Corman V.M., Guggemos W., et al. (2020)    | Nature                           | 2685            |
| 2        | A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19                                   | Cao B., Wang Y., Wen D., et al. (2020)                | New England Journal of Medicine  | 2668            |
| 3        | Dexamethasone in hospitalized patients with COVID-19   | Horby P., Lim W.S., Emberson J.R., et al. (2020)      | New England Journal of Medicine  | 2359            |
| 4        | Remdesivir for the treatment of COVID-19 — Final report  | Beigel J.H., Tomashek K.M., Dodd L.E., et al. (2020)  | New England Journal of Medicine  | 2186            |
| 5        | Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine  | Polack F.P., Thomas S.J., Kitchin N., et al. (2020)   | New England Journal of Medicine  | 2180            |
| 6        | World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)       | Sohrabi C., Alsafi Z., O'Neill N., et al. (2020)      | International Journal of Surgery | 1735            |
| 7        | Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science | Holmes E.A., O'Connor R.C., Perry V.H., et al. (2020) | The Lancet Psychiatry            | 1617            |
| 8        | The socio-economic implications of the coronavirus pandemic (COVID-19): A review                             | Nicola M., Alsafi Z., Sohrabi C., et al. (2020)       | International Journal of Surgery | 1506            |
| 9        | Remdesivir in adults with severe COVID-19: a randomized, double-blind, placebo-controlled, multicenter trial | Wang Y., Zhang D., Du G., et al. (2020)               | The Lancet                       | 1455            |
| 10       | The trinity of COVID-19: immunity, inflammation and intervention   | Tay M.Z., Poh C.M., Rénia L., MacAry P.A.,            | Nature Reviews Immunology        | 1388            |

|  |                  |  |  |
|--|------------------|--|--|
|  | Ng L.F.P. (2020) |  |  |
|--|------------------|--|--|

The virological assessment of hospitalized patients with COVID-2019 was reviewed by Wolfe et al., (2020) of the UK. The study was published in Nature and received 2685 citations in a short time. It shows that the study has received a lot of attention from the researchers. The effect of remdesivir was reported by Beigel et al., (2020). To examine the effect, they purposely applied a 10 days course of remdesivir and placebo to the 1062 patients and observed the result. They saw that patients treated with remdesivir quickly recovered than the patients treated without remdesivir. It also reduces tracheal infection of the COVID-19 confirmed patients. Holmes et al. (2020) have shown their interest to evaluate the diverse effects of the pandemic on society including social and mental health. They stress the collaborative and inter-disciplinary research and collection of data across the globe to find the fruitful result of the research. Nicola et al., (2020) also presented a review paper depicting the global socio-economic scenario due to the sudden advent of the calamitous virus. They tried to explore the changes pre- and post-pandemic situations in different sectors like education, production of commodities, the field of medicine, the food sector, etc. Sohrabi et al., (2020) made a review of the 2019 novel coronavirus and inferred that rigorous surveillance, minute observation, and hard work are urgently needed to comprehend the nature of the devastating virus. Tay et al., (2020) analysed the different mechanisms of SARS-CoV2, and emphasize immunopathogenesis. They inferred that T-cell may take an effective role to prevent the infection of the virus. They also emphasized more research in this direction. Wang, Y. et al., (2020) studied the viral infected adult patients admitted to the ten hospitals in the Hubei province of China. The patients were treated with a controlled dose of remdesivir drug but after due observation, no significant result has been obtained of the many discussed remdesivir drug.

### 4.3. China

Subsection 4.3 presents contribution of China in COVID-19 related research. Table 8 presents the top fifteen authors, subject area, and institution of China in terms of TP.

**Table 8. Leading authors, subject areas, and institutions in COVID-19 research in China**

| R  | Authors      | TP | Subject area                                 | TP   | Institution  | TP   |
|----|--------------|----|--|------|--|------|
| 1  | Lu, H.       | 57 | Medicine                                     | 8224 | Huazhong University of Science and Technology                      | 1484 |
| 2  | To, K.K.W.   | 46 | Biochemistry, Genetics and Molecular Biology | 2280 | Tongji Medical College   | 1324 |
| 3  | Yuen, K.Y.   | 46 | Immunology and Microbiology                  | 1563 | Chinese Academy of Sciences  | 891  |
| 4  | Chan, J.F.W. | 44 | Environmental Science                        | 1279 | Ministry of Education China  | 794  |
| 5  | Zhao, S.     | 42 | Social Sciences                              | 1233 | Fudan University   | 583  |
| 6  | Liu, L.      | 41 | Engineering                                  | 935  | Chinese Academy of Medical Sciences & Peking Union Medical College | 566  |
| 7  | Hu, Y.       | 40 | Pharmacology, Toxicology and Pharmaceutics   | 927  | Wuhan University   | 525  |
| 8  | Zhang, Z.    | 38 | Computer Science                             | 831  | University of Chinese Academy of Sciences                          | 498  |
| 9  | Ling, Y.     | 37 | Psychology                                   | 638  | Renmin Hospital of Wuhan University                                | 460  |
| 10 | Zhong, N.    | 37 | Multidisciplinary                            | 535  | Zhejiang University  | 442  |
| 11 | Gao, G.F.    | 36 | Chemistry                                    | 521  | Capital Medical University   | 440  |
| 12 | He, D.       | 36 | Mathematics                                  | 485  | Sun Yat-Sen University   | 432  |
| 13 | Bilal, M.    | 35 | Economics, Econometrics and Finance          | 444  | Peking University  | 402  |
| 14 | Cheung, T.   | 32 | Nursing                                      | 432  | Tsinghua University  | 397  |
| 15 | Hung, I.F.N. | 31 | Business, Management and Accounting          | 423  | Zhongnan Hospital of Wuhan University                              | 393  |

Professor H. Lu leads the list of leading authors in Table 8 followed by K.K.W. To and K. Y. Yuen. H. Lu has authored 57 research articles based on COVID-19 related issues. Expectedly, Chinese research works are evolved the majority in the area of medicine. Differing from the USA and UK, besides medicine, Chinese research works emphasized on research areas ‘Biochemistry, Genetics and Molecular Biology and ‘Immunology and Microbiology’. Huazhong University of Science and Technology, and Tongji Medical College are the leading institution in China for COVID-19 related research works. Seven institutions have more than five hundred publications. Table 9 presents the list of leading influential articles from China on COVID-19 related research works.

**Table 9. List of leading articles of China**

| R | Title  | Authors   | Journal                         | Citation |
|---|--|---|---------------------------------|----------|
| 1 | Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China | Huang C., Wang Y., Li X., Ren L., et al. (2020) | The Lancet                      | 18794    |
| 2 | Clinical characteristics of coronavirus disease 2019 in China                      | Guan W., Ni Z., Hu Y., et al. (2020)            | New England Journal of Medicine | 12264    |

|    |   |  |   |       |
|----|---|--|---|-------|
| 3  | Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study  | Zhou F., Yu T., Du R., Fan G., et al. (2020)             | The Lancet  | 10827 |
| 4  | A novel coronavirus from patients with pneumonia in China, 2019   | Zhu N., Zhang D., Wang W., et al. (2020)                 | New England Journal of Medicine                                   | 10317 |
| 5  | Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study   | Chen N., Zhou M., Dong X., et al. (2020)                 | The Lancet  | 8870  |
| 6  | A pneumonia outbreak associated with a new coronavirus of probable bat origin   | Zhou P., Yang X.-L., Wang X.-G., et al. (2020)           | Nature  | 7987  |
| 7  | Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding  | Lu R., Zhao X., Li J., et al. (2020)                     | The Lancet  | 4905  |
| 8  | A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster                            | Chan J.F.-W., Yuan S., Kok K.-H., et al. (2020)          | The Lancet  | 4074  |
| 9  | Pathological findings of COVID-19 associated with acute respiratory distress syndrome   | Xu Z., Shi L., Wang Y., Zhang J., et al. (2020)          | The Lancet Respiratory Medicine                                   | 3935  |
| 10 | A new coronavirus associated with human respiratory disease in China  | Wu F., Zhao S., Yu B., et al. (2020)                     | Nature  | 3819  |
| 11 | Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China                              | Wu C., Chen X., Cai Y., et al. (2020)                    | JAMA Internal Medicine  | 3426  |
| 12 | Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China | Wang C., Pan R., Wan X., Tan Y., Xu L., Ho C.S., Ho R.C. | International Journal of Environmental Research and Public Health | 2987  |
| 13 | A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19  | Cao B., Wang Y., Wen D., et al. (2020)                   | New England Journal of Medicine                                   | 2668  |
| 14 | Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China  | Mao L., Jin H., Wang M., et al. (2020)                   | JAMA Neurology  | 2655  |
| 15 | Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases   | Ai T., Yang Z., Hou H., et al. (2020)                    | Radiology   | 2335  |
| 16 | Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019  | Lai J., Ma S., Wang Y., et al. (2020)                    | JAMA Network Open   | 2174  |
| 17 | Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China   | Qin C., Zhou L., Hu Z., et al. (2020)                    | Clinical Infectious Diseases                                      | 1859  |
| 18 | Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2  | Yan R., Zhang Y., Li Y., et al. (2020)                   | Science   | 1824  |
| 19 | Clinical and immunological features of severe and moderate coronavirus disease 2019   | Chen G., Wu D., Guo W., et al. (2020)                    | Journal of Clinical Investigation                                 | 1812  |
| 20 | The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak- A n update on the status   | Guo Y.R., Cao Q. D., Hong Z.S., et al. (2020)            | Military Medical Research   | 1762  |

Huang et al. (2020) made a case study taking into account forty (41) patients admitted in a hospital in Wuhan city of China being infected by a 2019 novel coronavirus. The median age of the patients was 49 and they observed that pneumonia was common of all patients with different levels of chest injury and some of them have to be treated in ICU. But surprisingly it is seen that ICU patients are in a better position than non-ICU patients in terms of plasma level. The paper was published in the world-famous medical journal 'The Lancet' bearing a magnificent number of citations with 18794 ensuring its quality. To characterize the deadly virus, Guan et al. (2020) gathered data of 1099 patients from 552 hospitals with different demography of China. The paper got a remarkable number of citations with a total of 12264 within a very short time. After the investigations of 191 patients admitted to two hospitals in China (Jinyintan Hospital, and Wuhan Pulmonary Hospital), Zhou, F. et al. (2020) summarised that patient with more than  $1\mu\text{g/ml}$  d-dimer have a very high risk. The paper was published in the highly reputed medical journal 'The Lancet' and received over 10000 citations. Zhu et al. (2020) has given importance to the mode of transmission, an interval of reproduction, clinical spectrum, and above all stress on the determination of strategy how to check the spread of the virus. They also pointed out the continuous and minute observation of the characters of the virus. Investigation about the clinical and epidemiological characteristics of 99 patients from Wuhan Jinyintan Hospital has been done by Chen, N. et al. (2020), and they come to the conclusion that the virus has become very severe to the aged males having comorbidities. They also suggest more and deep investigation/study for the prediction of the risk of mortality. Zhou, P. et al. (2020) provided a detailed study of the 2019 novel SARS CoV-2 pointing out the possible responsible agent for current catastrophe in human life. They also notice the existence of nucleotide positive and viral-protein seroconversion of all patients with confirmed cases. They focus on more exploration in this regard. Lu et al. (2020) interpreted that the 2019 novel coronavirus has a strong affinity with the human receptor ACE-2. They also guessed that while bats may have been the original host, some animals may have acted as a catalyst to spread the virus to humans. After a careful examination of a household with six patients, Chan et al. (2020a) stressed the need of avoiding human-to-human transmission of the virus. Xu et al. (2020) hope that their research will help to explore pathogens, and will be able to assist in mitigating the mortality rate. After studying a patient admitted to the Central Hospital of Wuhan being infected by the virus who worked at the local seafood market in Wuhan city, Wu, C. et al. (2020) emphasized the importance of doing extensive research to explore the natural and

intermediate hosts. Note that, the article developed by Cao et al (2020) [SI No-13 in Table 9] has been described in both the USA, and the U.K., and the article presented by Mao et al. (2020) [SI No. 14 in Table 9] has been discussed earlier in the section of U.K. The Table 9 reveals that the leading articles of China have received a significant number of citations; four out of ten papers have got more than 10000 citations. Chinese articles get more citations as initial pieces of evidence about the impact of the 2019 novel coronavirus received from China. Researchers all over the world followed research outcomes and patient observation from various Chinese hospitals.

#### 4.4. Italy

Subsection 4.4 presents contribution of another badly COVID-19 affected country, Italy in COVID-19 related research. Table 10 presents the top fifteen authors, subject area, and institution of Italy based on the TP.

**Table 10. Leading authors, subject areas, and institutions in COVID-19 research in Italy**

| R  | Authors           | TP | Subject area                                 | TP   | Institution   | TP   |
|----|-------------------|----|--|------|---|------|
| 1  | Lippi, G.         | 87 | Medicine                                     | 7951 | Università degli Studi di Milano                            | 1140 |
| 2  | Landoni, G.       | 61 | Biochemistry, Genetics and Molecular Biology | 1757 | Sapienza Università di Roma                                 | 1129 |
| 3  | Ciceri, F.        | 55 | Immunology and Microbiology                  | 957  | Università degli Studi di Padova                            | 719  |
| 4  | Buonsenso, D.     | 53 | Social Sciences                              | 899  | Università degli Studi di Napoli Federico II                | 594  |
| 5  | Nicastri, E.      | 49 | Environmental Science                        | 809  | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 525  |
| 6  | Henry, B.M.       | 47 | Psychology                                   | 533  | Alma Mater Studiorum Università di Bologna                  | 492  |
| 7  | Ippolito, G.      | 47 | Pharmacology, Toxicology and Pharmaceutics   | 517  | Università degli Studi di Torino                            | 464  |
| 8  | Zangrillo, A.     | 47 | Neuroscience                                 | 470  | Università Cattolica del Sacro Cuore, Campus di Roma        | 434  |
| 9  | Mussini, C.       | 46 | Computer Science                             | 390  | Consiglio Nazionale delle Ricerche                          | 418  |
| 10 | Bassetti, M.      | 45 | Nursing                                      | 349  | Università degli Studi di Pavia                             | 399  |
| 11 | Bruno, R.         | 45 | Engineering                                  | 337  | Ospedale Maggiore Policlinico Milano                        | 393  |
| 12 | Mastroianni, C.M. | 42 | Multidisciplinary                            | 321  | Università degli Studi di Genova                            | 391  |
| 13 | Cecconi, M.       | 41 | Agricultural and Biological Sciences         | 293  | Università degli Studi della Campania Luigi Vanvitelli      | 387  |
| 14 | Girardis, M.      | 41 | Chemistry                                    | 261  | Università degli Studi di Milano-Bicocca                    | 383  |
| 15 | Franceschi, F.    | 40 | Health Professions                           | 260  | Università degli Studi di Roma Tor Vergata                  | 382  |

Professor Giuseppe Lippi from the University of Verona has the most (87) number of publications. Note that, Professor Lippi also leads in the USA. This is an incredible performance as he leads in two countries (USA and Italy) through collaborative works. Professor G. Landoni and F. Ciceri are in the second and third positions with 61 and 55 publications respectively. The top fifteen authors of Italy have more than or equal to forty publications. Among the 11476 publications, 7951 are in the area of medicine. ‘Biochemistry, Genetics and Molecular Biology’ and ‘Immunology and Microbiology’ are the other two leading research areas in Italy. There are more than eight hundred publications in the areas 'Social Sciences' and 'Environmental Science'. Interestingly, there are 533 publications on Psychology. This evidence shows that fear of COVID-19 and its obligations has a huge impact on public psychological health. Università degli Studi di Milano and Sapienza Università di Roma are two the leading institutions with 1140 and 1129 publications on COVID-19 related research. Five universities of Italy have more than five hundred publications.

#### 4.5. India

Table 11 presents the top fifteen authors, subject area, and institution of Italy based on the TP.

**Table 11. Leading authors, subject areas, and institutions in COVID-19 research in India**

| R | Authors       | TP  | Subject area                                 | TP   | Institution  | TP  |
|---|---------------|-----|--|------|--|-----|
| 1 | Dhama, K.     | 109 | Medicine                                     | 5314 | All India Institute of Medical Sciences, New Delhi                 | 526 |
| 2 | Tiwari, R.    | 56  | Biochemistry, Genetics and Molecular Biology | 1749 | Postgraduate Institute of Medical Education & Research, Chandigarh | 377 |
| 3 | Bhatnagar, S. | 40  | Social Sciences                              | 1228 | Datta Meghe Institute of Medical Sciences Deemed to be University  | 215 |
| 4 | Misra, S.     | 39  | Pharmacology, Toxicology and Pharmaceutics   | 1156 | Manipal Academy of Higher Education                                | 208 |
| 5 | Vaishya, R.   | 37  | Computer Science                             | 792  | University of Delhi  | 200 |
| 6 | Misra, A.     | 36  | Environmental Science                        | 764  | Saveetha Institute of Medical and Technical Sciences               | 175 |
| 7 | Malik, Y.S.   | 34  | Immunology and Microbiology                  | 743  | Indian Council of Medical Research                                 | 170 |
| 8 | Sharun, K.    | 33  | Engineering                                  | 638  | Saveetha Dental College And Hospitals                              | 157 |
| 9 | Medhi, B.     | 32  | Agricultural and                             | 484  | Amity University   | 153 |



|    |                         |    |                                     |     |  |     |
|----|-------------------------|----|-------------------------------------|-----|--|-----|
|    |                         |    | Biological Sciences                 |     |  |     |
| 10 | Rodriguez-Morales, A.J. | 31 | Business, Management and Accounting | 431 | Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow | 144 |
| 11 | Sah, R.                 | 31 | Economics, Econometrics and Finance | 401 | Indian Council of Agricultural Research                          | 137 |
| 12 | Javaid, M.              | 29 | Mathematics                         | 397 | All India Institute of Medical Sciences, Jodhpur                 | 133 |
| 13 | Rabaan, A.A.            | 29 | Chemistry                           | 383 | Banaras Hindu University   | 124 |
| 14 | Sharma, P.              | 29 | Chemical Engineering                | 247 | Indian Veterinary Research Institute                             | 122 |
| 15 | Suri, V.                | 28 | Neuroscience                        | 247 | Jamia Millia Islamia   | 122 |

Professor K Dhama, principal scientist of the Indian Veterinary Research Institute, Izatnagar has authored a total of 107 papers. He is the most productive author for India as well as the World in COVID-19 related research. Professor R. Tiwari is in the second position on the list of leading Indian authors with 56 publications. Among the 10726 articles of India 5314 articles are published in medicine-based journals and 1749 in the area 'Biochemistry, Genetics and Molecular Biology'. More than twelve per cent of articles were published in 'Social Sciences' journals. Indian researchers also focused on 'Pharmacology, Toxicology and Pharmaceutics' journals and published 1156 articles in this area. All India Institute of Medical Sciences, New Delhi is the leading institution in India with 526 publications. Five institutions of India in Table 11 have more than 200 publications.

#### 4.6. Canada

Table 12 presents the top fifteen authors, subject area, and institution of Canada based on the TP.

**Table 12. Leading authors, subject areas, and institutions in COVID-19 research in Canada**

| R | Authors        | TP | Subject area                                 | TP   | Institution                        | TP   |
|---|----------------|----|--|------|------------------------------------|------|
| 1 | Bragazzi, N.L. | 56 | Medicine                                     | 4049 | University of Toronto              | 1527 |
| 2 | Murthy, S.     | 35 | Social Sciences                              | 1010 | The University of British Columbia | 814  |
| 3 | Mubareka, S.   | 26 | Biochemistry, Genetics and Molecular Biology | 669  | McMaster University                | 535  |
| 4 | Dyer, O.       | 24 | Immunology and Microbiology                  | 408  | University of Alberta              | 517  |
| 5 | Slutsky, A.S.  | 23 | Environmental Science                        | 399  | Université McGill                  | 480  |
| 6 | Halwani, R.    | 21 | Psychology                                   | 388  | University of Calgary              | 439  |
| 7 | Rochweg, B.    | 21 | Multidisciplinary                            | 259  | University of Ottawa               | 426  |
| 8 | Abrams, E.M.   | 20 | Neuroscience                                 | 258  | The University of Western Ontario  | 314  |

|    |                   |    |  |     |  |     |
|----|-------------------|----|--|-----|--|-----|
| 9  | Asmundson, G.J.G. | 20 | Nursing                                    | 257 | University of Montreal                             | 296 |
| 10 | Chattu, V.K.      | 20 | Engineering                                | 230 | University of Manitoba                             | 285 |
| 11 | Finzi, A.         | 20 | Computer Science                           | 220 | University Health Network<br>University of Toronto | 256 |
| 12 | Greenshaw, A.J.   | 19 | Agricultural and Biological Sciences       | 207 | Dalhousie University                               | 256 |
| 13 | Agyapong, V.I.O.  | 18 | Pharmacology, Toxicology and Pharmaceutics | 205 | York University                                    | 246 |
| 14 | Lamontagne, F.    | 18 | Business, Management and Accounting        | 202 | Saint Michael's Hospital University of Toronto     | 232 |
| 15 | Taylor, S.        | 18 | Economics, Econometrics and Finance        | 182 | Hospital for Sick Children University of Toronto   | 217 |

Nicola Luigi Bragazzi from York University, Toronto is the leading author in the list of productive authors from Canada (see Table 12). S. Murthy has 35 publications on COVID-19 and gets the second position in Canada. The top eleven authors in Table 12 have more than or equal to twenty publications. Among the 6516 articles of Canada, 4049 articles are published in medicine-based journals and 1010 in the area of 'Social Sciences' journals. More than ten percent of articles were published in 'Biochemistry, Genetics and Molecular Biology' journals. The University of Toronto leads comprehensively with 1527 publications followed by The University of British Columbia in the list of productive institutions from Canada. Seven institutions of Canada in Table 12 have more than 400 publications.

#### 4.7. Spain

Table 13 presents the top fifteen authors, subject area, and institution of Spain based on the TP.

**Table 13. Leading authors, subject areas, and institutions in COVID-19 research in Spain**

| R | Authors              | TP | Subject area                                 | TP   | Institution                                     | TP  |
|---|----------------------|----|--|------|---|-----|
| 1 | Smith, L.            | 37 | Medicine                                     | 4061 | Universitat de Barcelona                        | 528 |
| 2 | Torres, A.           | 30 | Social Sciences                              | 786  | Hospital Clinic Barcelona                       | 518 |
| 3 | Jacob, L.            | 27 | Environmental Science                        | 762  | Universitat Autònoma de Barcelona               | 429 |
| 4 | Soriano, A.          | 27 | Biochemistry, Genetics and Molecular Biology | 591  | Universidad Complutense de Madrid               | 429 |
| 5 | Lechien, J.R.        | 25 | Immunology and Microbiology                  | 417  | Hospital General Universitario Gregorio Marañón | 370 |
| 6 | Fernández-Ruiz, M.   | 24 | Psychology                                   | 380  | Instituto de Salud Carlos III                   | 348 |
| 7 | Koyanagi, A.         | 24 | Nursing                                      | 285  | Hospital Universitario La Paz                   | 313 |
| 8 | Chiesa-Estomba, C.M. | 23 | Computer Science                             | 261  | Hospital Universitari Vall d'Hebron             | 271 |
| 9 | Mullol, J.           | 23 | Engineering                                  | 236  | Hospital Universitario 12 de                    | 267 |

|    |                   |    |  |     | Octubre  |     |
|----|-------------------|----|--|-----|--|-----|
| 10 | Estrada, V.       | 22 | Energy                                     | 235 | Institut d'Investigacions Biomèdiques August Pi i Sunyer - IDIBAPS     | 256 |
| 11 | Ferrer, R.        | 22 | Neuroscience                               | 234 | Universitat de València  | 254 |
| 12 | Horcajada, J.P.   | 22 | Business, Management and Accounting        | 207 | Hospital Universitari de Bellvitge                                     | 243 |
| 13 | Agache, I.        | 21 | Multidisciplinary                          | 196 | Hospital Clínico San Carlos de Madrid                                  | 236 |
| 14 | Aguado, J.M.      | 21 | Agricultural and Biological Sciences       | 189 | Universidad Autónoma de Madrid   | 229 |
| 15 | García-Azorín, D. | 21 | Pharmacology, Toxicology and Pharmaceutics | 188 | Centro de Investigación Biomédica en Red de Enfermedades Respiratorias | 218 |

L. Smith is the leading author in the list of productive authors from Spain (see Table 13) followed by A. Torres. The top five authors in Table 13 have more than or equal to twenty-five publications. The top three leading areas of Spanish authors in COVID-19 research are 'Medicine', 'Social Sciences', and 'Environmental Science'. It is noticeable that more than twelve percent of articles of Spanish authors in COVID-19 research are published in 'Environmental Science' related journals. The University of Barcelona leads among the Spanish institutions with 528 publications followed by Hospital Clinic Barcelona, which has 518 publications in COVID-19 research. Seven institutions of Spain in Table 13 have more than 300 publications.

**Table 14.** List of leading articles of Italy, India, Canada, Spain

|       | R | Title   | Authors   | Journal  | Citation |
|-------|---|---|---|--|----------|
| Italy | 1 | Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy                                | Grasselli G., Zangrillo A., Zanella A., et al. (2020)           | JAMA - Journal of the American Medical Association | 2230     |
|       | 2 | COVID-19 and Italy: what next?  | Remuzzi A., Remuzzi G.  | The Lancet   | 1444     |
|       | 3 | Compassionate use of remdesivir for patients with severe COVID-19   | Grein J., Ohmagari N., Shin D., et al. (2020)                   | New England Journal of Medicine                    | 1344     |
|       | 4 | COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review           | Bikdeli B., Madhavan M.V., Jimenez D., et al. (2020)            | Journal of the American College of Cardiology      | 1224     |
|       | 5 | The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak   | Chinazzi M., Davis J.T., Ajelli M., et al. (2020)               | Science  | 1164     |
|       | 6 | Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study | Lechien J.R., Chiesa-Estomba C.M., De Siati D.R., et al. (2020) | European Archives of Oto-Rhino-Laryngology         | 1068     |
| India | 1 | A Review of Coronavirus Disease-2019  | Singhal T.  | Indian Journal of                                  | 1097     |

|        |   |  |   |   |      |
|--------|---|--|---|---|------|
|        |   | (COVID-19)   |   | Pediatrics                                    |      |
|        | 2 | COVID-19 and mental health: A review of the existing literature  | Rajkumar R.P.   | Asian Journal of Psychiatry                   | 1042 |
|        | 3 | Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis   | Rodriguez-Morales A.J., Cardona-Ospina J.A., Gutiérrez-Ocampo E., et al. (2020) | Travel Medicine and Infectious Disease        | 1006 |
| Canada | 1 | Compassionate use of remdesivir for patients with severe COVID-19  | Grein J., Ohmagari N., Shin D., et al. (2020)                                   | New England Journal of Medicine               | 1344 |
|        | 2 | COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review            | Bikdeli B., Madhavan M.V., Jimenez D et al. (2020)                              | Journal of the American College of Cardiology | 1224 |
|        | 3 | Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis | Chu D.K., Akl E.A., Duda S., et al. (2020)                                      | The Lancet                                    | 1181 |
|        | 4 | Fair allocation of scarce medical resources in the time of COVID-19  | Emanuel E.J., Persad G., Upshur R., et al. (2020)                               | New England Journal of Medicine               | 1165 |
|        | 5 | Using social and behavioural science to support COVID-19 pandemic response   | Bavel J.J.V., Baicker K., Boggio P.S., et al. (2020)                            | Nature Human Behaviour                        | 1154 |
|        | 6 | Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study  | Lechien J.R., Chiesa-Estomba C.M., De Siati D.R., et al. (2020)                 | European Archives of Oto-Rhino-Laryngology    | 1068 |
|        | 7 | A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)                           | Jin Y.-H., Cai L., Cheng Z.-S., Cheng H., et al. (2020)                         | Military Medical Research                     | 1003 |
| Spain  | 1 | Remdesivir for the treatment of COVID-19 — Final report  | Beigel J.H., Tomashek K.M., Dodd L.E., et al. (2020)                            | New England Journal of Medicine               | 2186 |
|        | 2 | Compassionate use of remdesivir for patients with severe COVID-19  | Grein J., Ohmagari N., Shin D., et al. (2020)                                   | New England Journal of Medicine               | 1344 |
|        | 3 | COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review            | Bikdeli B., Madhavan M.V., Jimenez D., et al. (2020)                            | Journal of the American College of Cardiology | 1224 |
|        | 4 | Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study  | Lechien J.R., Chiesa-Estomba C.M., De Siati D.R., et al. (2020)                 | European Archives of Oto-Rhino-Laryngology    | 1068 |

### **Discussion on the leading articles of Italy, India, Canada, Spain**

#### **Italy**

The cohort study of Grasselli et al. (2020) over 3988 critical patients in the Lombardy region of Italy reveals the higher mortality rate of the patients. These patients have an urgent need of ICU, and Invasive Mechanical Ventilation (IMV). Remuzzi et al (2020) attempted to depict a picture of healthcare scenarios of Italy after the outbreak of the pandemic. They also reiterated that if the trends of the graph persist, the Italian Government has to take immediate action to increase the health infrastructure to get rescue from such a terrible pandemic situation. Grein et al. (2020) used the remdesivir drug among the 61 hospitalized confirmed infected patients with an oxygen level of less than or equal to 94 oxygen levels and found that this drug may be beneficial to the critically ill. Chinazzi et al. (2020) use a global meta-population disease transmission model. They concluded that inter-national travel restrictions could slow the spread of the novel coronavirus. They also found that early detection, hand washing, self-isolation, and household quarantine are more helpful than travel limitations in preventing the spread of the deadly virus. Lechien et al. (2020) investigated the situation of hospitalized patients with confirmed infection to see the existence of olfactory and gustatory disorder among the patients and observed that these symptoms are frequent/prevalent among European patients. They also stressed the need of identifying the symptom anosmia or ageusia which is regarded as a crucial symptom of COVID-infected patients. Bikdeli et al. (2020) looked at the pathogenesis, epidemiology, and outcomes of the patients and highlighted the need for precaution having a thrombotic disease.

## **India**

Singhal et al. (2020) presented a comprehensive review of COVID-19. In this review paper, the author sheds light on the different features like symptoms of the infected people, and process of treatment, etc. Rajkumar et al. (2020) discussed that COVID-19 has a major adverse effect on the mental health of the common people like anxiety, depression, and mental stress. They also summarized that more research may unfold different aspects in this regard especially for the people belonging at a higher risk due to poor health. After going through the 27 articles Rodriguez-Morales et al. (2020) presented a systematic review and meta-analysis in Indian perspective with three basic objectives – to summarize the results obtained from various laboratory-based clinical examinations, and observations, to review the infrastructure for critical patients, and to estimate the prevalence/frequency of co-morbid patients.

## **Canada**

After going through some research papers related to social and behavioural science Baval et al. (2020) talked about the prevention of threat, social, and behavioural changes, improvement of science communication, leadership, stress, etc. during the pandemic. They also pointed out the research insights of the earlier published papers as well as the gaps. They hope that the paper may help/assist the policymaker to reduce the potentially fatal impacts of COVID-19 by taking immediate intervention in this regard. Chu et al. (2020) presented a systematic review and meta-analysis by collecting a dataset from 21 standard sources recognized by the World Health Organisation (WHO) across 16 countries of six continents. They used the data after careful and proper screening on both health care workers and common people. They observe that close contact with human beings may accelerate the spread of the virus. After a detailed study, they suggest the three main ways for prevention from the spread of SARS-CoV-2 -firstly on keeping greater than a 1-meter distance between each other, second the optimal use of masks namely N-95, surgical and 12–16-layer cotton masks, and the third is the use of goggles, face shields, etc. for protection of eyes. They added that N-95 masks are more effective than surgical masks for health care workers, and the common people may use N-95 masks as well as surgical or cotton masks. Jin et al., (2020) prepared a guideline for the diagnosis and treatment of COVID-19 infected patients based on the available primary data of Zhongan Hospital of Wuhan University. Since the fatal virus is transmitted through droplets, they strongly recommended avoiding unnecessary travel and advised to stay at home. They recommended some measures for frontline line workers like the doctors, nurses, scientists, police, and other people associated with the hospitals, etc. They have suggested various measures for the treatment of the infected people like continuous monitoring with different blood tests, and other clinical examinations. They also suggested oxygen therapy and ECMO support for critical patients. They also pointed out a very controversial matter of whether the drug lopinavir and ritonavir are beneficial or not for corona-infected patients. After deep observation, they summarised that these drugs may be beneficial for the patients if applied at an early stage, but give no fruitful result for late application. They also added that further exploration is needed in this regard. Emanuel et al. (2000) proposed six recommendations for equal distribution, and optimal use of scarce medical resources, as well as a roadmap for equal access to facilities, and opportunity for all. Through their recommendations, they brought attention to a few key points. According to their opinion, equal emphasis should be

equally given to all types of patients (both-COVID, and non-COVID), strong efforts should be made to save the most lives and maximum benefits of individuals, testing, use of PPE should be enhanced, ICU for critical patients should be provided, and special attention is to be given on the researchers as they can do their work freely, and fearlessly for the greater benefit of the society in future. They also stated that patients should be given priority based on scientific evidence rather than on a first-come-first-served basis.

## **Spain**

List of leading articles of Spain are already discussed earlier as these are concurrently listed in another countries namely U.K., Italy, and Canada.

### **4.8. Germany**

Table 15 presents the top fifteen authors, subject area, and institution of Germany based on the TP.

**Table 15. Leading authors, subject areas, and institutions in COVID-19 research in Germany**

| <b>R</b> | <b>Authors</b>   | <b>TP</b> | <b>Subject area</b>                          | <b>TP</b> | <b>Institution</b>                         | <b>TP</b> |
|----------|------------------|-----------|--|-----------|--|-----------|
| 1        | Drosten, C.      | 58        | Medicine                                     | 3446      | Charité – Universitätsmedizin Berlin       | 525       |
| 2        | Corman, V.M.     | 54        | Biochemistry, Genetics and Molecular Biology | 894       | Ludwig-Maximilians-Universität München     | 364       |
| 3        | Dittmer, U.      | 40        | Social Sciences                              | 752       | Freie Universität Berlin                   | 270       |
| 4        | Ciesek, S.       | 33        | Immunology and Microbiology                  | 626       | Universität Heidelberg                     | 260       |
| 5        | Netea, M.G.      | 32        | Environmental Science                        | 407       | Technical University of Munich             | 250       |
| 6        | Lütgehetmann, M. | 29        | Multidisciplinary                            | 340       | Berliner Institut für Gesundheitsforschung | 248       |
| 7        | Kluge, S.        | 28        | Psychology                                   | 311       | Universitätsklinikum Hamburg-Eppendorf     | 237       |
| 8        | Klimek, L.       | 27        | Neuroscience                                 | 252       | Klinikum der Universität München           | 233       |
| 9        | Sander, L.E.     | 26        | Economics, Econometrics and Finance          | 251       | Eberhard Karls Universität Tübingen        | 187       |
| 10       | Bousquet, J.     | 25        | Pharmacology, Toxicology and Pharmaceutics   | 246       | Universität Duisburg-Essen                 | 186       |
| 11       | Kurth, F.        | 25        | Computer Science                             | 241       | Universität Freiburg                       | 183       |
| 12       | Merle, U.        | 25        | Business, Management and Accounting          | 218       | University of Cologne                      | 168       |
| 13       | Dreher, M.       | 24        | Engineering                                  | 192       | Harvard Medical School                     | 167       |
| 14       | Meybohm, P.      | 23        | Agricultural and Biological Sciences         | 184       | Medizinische Hochschule Hannover MHH       | 167       |

|    |            |    |           |     |                                      |     |
|----|------------|----|-----------|-----|--------------------------------------|-----|
| 15 | Witzke, O. | 23 | Chemistry | 175 | Goethe-Universität Frankfurt am Main | 166 |
|----|------------|----|-----------|-----|--------------------------------------|-----|

German virologist Christian Drosten leads the list of productive authors in Table 15 with 58 publications in COVID-19 research closely followed by another virologist Victor M. Corman from Charité – Universitätsmedizin Berlin, who has 54 publications. The top five authors from Germany in Table 15 have more than thirty publications. The top three leading areas of German authors in COVID-19 research are 'Medicine', 'Biochemistry, Genetics and Molecular Biology', and 'Social Sciences'. Charité – Universitätsmedizin Berlin leads comprehensively among the German institutions with 525 publications followed by Ludwig-Maximilians-Universität München. The top five institutions of Germany in Table 15 have more than or equal to 250 publications.

**Table 16. List of leading articles of Germany**

| R  | Title   | Authors   | Journal                                       | Citation |
|----|---|---|---|----------|
| 1  | SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor  | Hoffmann M., Kleine-Weber H., Schroeder S., et al. (2020) | Cell  | 6634     |
| 2  | Virological assessment of hospitalized patients with COVID-2019   | Wölfel R., Corman V.M., Guggemos W., et al. (2020)        | Nature  | 2685     |
| 3  | Remdesivir for the treatment of COVID-19 — Final report   | Beigel J.H., Tomashek K.M., Dodd L.E., et al. (2020)      | New England Journal of Medicine               | 2186     |
| 4  | Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine   | Polack F.P., Thomas S.J., Kitchin N., et al. (2020)       | New England Journal of Medicine               | 2180     |
| 5  | Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19  | Ackermann M., Verleden S.E., Kuehnel M., et al. (2020)    | New England Journal of Medicine               | 1810     |
| 6  | Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents  | Kampf G., Todt D., Pfaender S., Steinmann E. (2020)       | Journal of Hospital Infection                 | 1495     |
| 7  | Compassionate use of remdesivir for patients with severe COVID-19   | Grein J., Ohmagari N., Shin D., Diaz G., et al. (2020)    | New England Journal of Medicine               | 1344     |
| 8  | The reproductive number of COVID-19 is higher compared to SARS coronavirus  | Liu Y., Gayle A.A., Wilder-Smith A., Rocklöv J. (2020)    | Journal of Travel Medicine                    | 1286     |
| 9  | COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review | Bikdeli B., Madhavan M.V., Jimenez D., et al. (2020)      | Journal of the American College of Cardiology | 1224     |
| 10 | Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors  | Zhang L., Lin D., Sun X., et al. (2020)                   | Science                                       | 1078     |



The 2019-nCoV has posed a serious global problem. People across the world are directionless to find a way to save themselves from the grasp of the deadly virus. Researchers of almost all the countries are engaged to find the way of prevention of infection, and method of treatment, etc. German researchers have also come forward to carry on the research in this regard. Hoffmann et al., (2020) deeply investigated the existence of any cell or any kind of host in the human body that has an affinity to attract the SARS CoV-2 or if there exist any matters that prevent the access of virus in the human body. They observed that ACE2 accelerates the easy entrance of the virus into the human body. They also demanded that the entry of lethal virus may be blocked by an inhibitor of the cellular series protease TMPRSS2 which is employed by SAERS-CoV-2 for S protein priming. Kampf et al., (2020) inquired whether inanimate things like metal, glass, or plastic are regarded as a carrier of coronavirus or not. They inferred that such inanimate things may persist the virus for up to 9 days. Chemical reagents like ethanol, sodium hypochlorite, and hydrogen peroxide can disinfect the virus within one minute up to a certain percentage. The positivity rate ( $R_0$ ) is used to represent the speed/rate of virus's transmissibility. Positivity rate of the COVID-19 virus was estimated by Liu et al. (2020). They show that if  $R_0$  is greater than one ( $R_0 > 1$ ), infection is likely to increase, and if it is less than one ( $R_0 < 1$ ), infection is going to diminish. According to their estimate, the mean  $R_0$  is 3.28 in mid-February, 2020 which is greater than WHO's estimate. Zhang et al (2020) analyzed the x-ray crystal structure of SARs-CoV-2 in two different crystal forms, at 1.95 and 2.20 Å resolution, to identify the main protease and its complex (M pro or 3CL pro) which cuts the polyproteins translated from viral RNA to yield functional viral proteins. They also tried to provide a useful framework to find pyridine-containing inhibitors to discover anti-coronaviral drugs.

#### **4.9. Australia**

Table 17 presents the top fifteen authors, subject area, and institution of Australia based on the TP.

**Table 17. Leading authors, subject areas, and institutions in COVID-19 research in Australia**

| <b>R</b> | <b>Authors</b>   | <b>TP</b> | <b>Subject area</b>                          | <b>TP</b> | <b>Institution</b>                               | <b>TP</b> |
|----------|------------------|-----------|--|-----------|--|-----------|
| 1        | Lippi, G.        | 25        | Medicine                                     | 3115      | University of Melbourne                          | 856       |
| 2        | MacIntyre, C.R.  | 25        | Social Sciences                              | 1297      | Monash University                                | 729       |
| 3        | Moni, M.A.       | 24        | Biochemistry, Genetics and Molecular Biology | 536       | The University of Sydney                         | 686       |
| 4        | Subbarao, K.     | 23        | Environmental Science                        | 438       | UNSW Sydney                                      | 650       |
| 5        | Holmes, E.C.     | 21        | Business, Management and Accounting          | 419       | The University of Queensland                     | 535       |
| 6        | Morawska, L.     | 20        | Immunology and Microbiology                  | 351       | Deakin University                                | 280       |
| 7        | Robinson, P.C.   | 20        | Psychology                                   | 348       | Faculty of Medicine, Nursing and Health Sciences | 274       |
| 8        | Islam, S.M.S.    | 19        | Nursing                                      | 323       | University of Technology Sydney                  | 236       |
| 9        | Ratten, V.       | 19        | Economics, Econometrics and Finance          | 263       | The Australian National University               | 220       |
| 10       | Xiang, Y.T.      | 19        | Computer Science                             | 245       | The University of Western Australia              | 220       |
| 11       | Dua, K.          | 18        | Arts and Humanities                          | 236       | Queensland University of Technology              | 218       |
| 12       | Savulescu, J.    | 18        | Engineering                                  | 233       | Griffith University                              | 208       |
| 13       | Wheatley, A.K.   | 18        | Health Professions                           | 187       | The University of Adelaide                       | 192       |
| 14       | Williamson, D.A. | 18        | Pharmacology, Toxicology and Pharmaceutics   | 184       | The University of Newcastle, Australia           | 189       |
| 15       | Alhumaid, S.     | 17        | Multidisciplinary                            | 176       | UNSW Medicine                                    | 189       |

Italian professor Giuseppe Lippi from the University of Verona and Australian Professor C Raina MacIntyre from Kirby Institute are leading jointly in the list of most productive authors in Australian publications related to COVID-19. The performance of Professor Giuseppe Lippi confirms well collaboration of Italy and Australia in COVID-19 related research. The top seven authors in Table 17 have more than or equal to twenty publications. Australian research papers are mostly published in medical journals. A notable 22% of research papers of Australia are published in social science-based journals. The University of Melbourne leads comprehensively among the Australian institutions with 856 publications followed by Monash University which has 729 publications in COVID-19. The top five institutions of Australia in Table 17 have more than 500 publications.

**Table 18. List of leading articles of Australia**

| R | Title   | Authors  | Journal  | Citation |
|---|---|--|--|----------|
| 1 | Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding                            | Lu R., Zhao X., Li J., et al. (2020)                               | The Lancet   | 4905     |
| 2 | A new coronavirus associated with human respiratory disease in China  | Wu F., Zhao S., Yu B., et al. (2020)                               | Nature   | 3819     |
| 3 | Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science  | Holmes E.A., O'Connor R.C., Perry V.H., et al. (2020)              | The Lancet Psychiatry                              | 1617     |
| 4 | COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review | Bikdeli B., Madhavan M.V., Jimenez D., et al. (2020)               | Journal of the American College of Cardiology      | 1224     |
| 5 | Using social and behavioural science to support COVID-19 pandemic response  | Bavel J.J.V., Baicker K., Boggio P.S., et al. (2020)               | Nature Human Behaviour                             | 1154     |
| 6 | Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors   | Jin Z., Du X., Xu Y., Deng Y., et al. (2020)                       | Nature   | 1149     |
| 7 | Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review  | Wiersinga W.J., Rhodes A., Cheng A.C., Peacock S.J., Prescott H.C. | JAMA - Journal of the American Medical Association | 1093     |

#### 4.10. France

**Table 19.** Leading authors, subject areas, and institutions in COVID-19 research in France

| R  | Authors         | TP | Subject area                                 | TP   | Institution  | TP   |
|----|-----------------|----|--|------|--|------|
| 1  | Raoult, D.      | 46 | Medicine                                     | 3215 | Inserm   | 1358 |
| 2  | Lechien, J.R.   | 40 | Biochemistry, Genetics and Molecular Biology | 665  | AP-HP Assistance Publique - Hopitaux de Paris      | 886  |
| 3  | Dyer, O.        | 36 | Immunology and Microbiology                  | 511  | CNRS Centre National de la Recherche Scientifique  | 810  |
| 4  | Lescure, F.X.   | 36 | Social Sciences                              | 272  | Université de Paris                                | 688  |
| 5  | Lina, B.        | 34 | Nursing                                      | 260  | Sorbonne Université                                | 526  |
| 6  | Colson, P.      | 33 | Environmental Science                        | 228  | Université Paris-Saclay                            | 424  |
| 7  | Saussez, S.     | 33 | Pharmacology, Toxicology and Pharmaceutics   | 206  | Aix Marseille Université                           | 359  |
| 8  | La Scola, B.    | 32 | Multidisciplinary                            | 194  | Hôpital Universitaire Pitié Salpêtrière            | 252  |
| 9  | Gautret, P.     | 29 | Neuroscience                                 | 185  | Université de Montpellier                          | 227  |
| 10 | Lagier, J.C.    | 29 | Economics, Econometrics and Finance          | 173  | Université Claude Bernard Lyon 1                   | 221  |
| 11 | Fafi-Kremer, S. | 28 | Business, Management and Accounting          | 169  | CHU de Lyon  | 220  |
| 12 | Bousquet, J.    | 27 | Psychology                                   | 169  | Université de Versailles Saint-Quentin-en-Yvelines | 210  |
| 13 | Visseaux, B.    | 27 | Agricultural and Biological Sciences         | 154  | Les Hôpitaux Universitaires de Strasbourg          | 193  |
| 14 | Yazdanpanah, Y. | 27 | Engineering                                  | 123  | Institut Pasteur, Paris                            | 186  |
| 15 | Jacob, L.       | 26 | Computer Science                             | 120  | Hôpital Bichat-Claude-                             | 176  |

|   |  |  |  |               |  |
|---|--|--|--|---------------|--|
| 5 |  |  |  | Bernard AP-HP |  |
|---|--|--|--|---------------|--|

Professor Didier Raoult from Aix Marseille Université, France has 46 publications in COVID-19 related research, leads the list of most productive authors in France. Professor J.R. Lechien is the second-ranked author in France with 40 publications in COVID-19 based research. The top eight authors in Table 19 have more than thirty publications. The top three leading subject areas of France in COVID-19 research are '*Medicine*', '*Biochemistry, Genetics and Molecular Biology*', and '*Immunology and Microbiology*'. The National Institute of Health and Medical Research (Inserm) leads comprehensively among the Australian institutions with 1358 publications followed by AP-HP Assistance Publique - Hopitaux de Paris which has 886 publications in COVID-19. CNRS Centre National de la Recherche Scientifique also shows important presence among the institutions in France. The top five institutions of France in Table 19 have more than 500 publications.

**Table 20:** List of leading articles of France

| R | Title   | Authors   | Journal                                       | Citation |
|---|---|---|---|----------|
| 1 | Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial  | Gautret P., Lagier J.-C., Parola P., et al. (2020)              | International Journal of Antimicrobial Agents | 2656     |
| 2 | Compassionate use of remdesivir for patients with severe COVID-19   | Grein J., Ohmagari N., Shin D., et al. (2020)                   | New England Journal of Medicine               | 1344     |
| 3 | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing   | Gordon D.E., Jang G.M., Bouhaddou M., et al. (2020)             | Nature  | 1291     |
| 4 | COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review           | Bikdeli B., Madhavan M.V., Jimenez D., et al. (2020)            | Journal of the American College of Cardiology | 1224     |
| 5 | High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study  | Helms J., Tacquard C., Severac F., et al. (2020)                | Intensive Care Medicine                       | 1089     |
| 6 | Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study | Lechien J.R., Chiesa-Estomba C.M., De Siati D.R., et al. (2020) | European Archives of Oto-Rhino-Laryngology    | 1068     |

Gautret et al., (2020) assayed whether hydroxychloroquine, and azithromycin are effective or not in lowering the viral load in covid infected patients. Based on a short sample, they observed that hydroxy chlorine helps lessen the viral load. They also inferred that using azithromycin in

conjunction with hydroxychloroquine is more effective. Based on some clinical trials, Helms, et al., (2020) found that CT pulmonary angiography (CTPA) may strongly assist the severe covid patients with high pulmonary embolism (PE). They also showed that lung ultrasonography alone is unable to detect/uncover the proper cause of deterioration of covid patients. CTPA is extremely useful to explore the unknown and peculiar characteristics/symptoms in such cases. Gordon et al., (2020) made a chemo-proteomic analysis to discover effective drugs for the treatment of covid patients. They also stressed the deciphering of the virus's mechanism responsible for it. They expect that their study will show a new avenue to fight against the different viruses along with the coronavirus.

#### 4.11. Leading authors, subject areas, and institutions of remaining 15 countries

**Table 21.** Leading authors, subject areas, and institutions in COVID-19 research of remaining 15 countries

|                  | R | Authors          | TP | Subject area                                 | TP   | Institutions  | TP   |
|------------------|---|------------------|----|--|------|---|------|
| <b>Brazil</b>    | 1 | Giovanetti, M.   | 33 | Medicine                                     | 2892 | Universidade de São Paulo                                     | 1074 |
|                  | 2 | Malta, D.C.      | 28 | Social Sciences                              | 504  | Fundacao Oswaldo Cruz   | 409  |
|                  | 3 | Rocco, P.R.M.    | 25 | Biochemistry, Genetics and Molecular Biology | 487  | Universidade Federal de São Paulo                             | 346  |
|                  | 4 | Szwarcwald, C.L. | 23 | Immunology and Microbiology                  | 398  | Universidade Federal do Rio de Janeiro                        | 316  |
|                  | 5 | Sabino, E.C.     | 22 | Nursing                                      | 357  | Universidade Federal de Minas Gerais                          | 313  |
| <b>Turkey</b>    | 1 | Karabay, O.      | 27 | Medicine                                     | 2570 | University of Health Sciences                                 | 564  |
|                  | 2 | Yıldırım, M.     | 26 | Biochemistry, Genetics and Molecular Biology | 369  | Hacettepe Üniversitesi  | 238  |
|                  | 3 | Arslan, G.       | 25 | Social Sciences                              | 321  | Istanbul Üniversitesi   | 176  |
|                  | 4 | Baleanu, D.      | 25 | Immunology and Microbiology                  | 302  | Ankara Üniversitesi   | 145  |
|                  | 5 | Dheir, H.        | 18 | Nursing                                      | 191  | İstanbul University-Cerrahpaşa Cerrahpaşa Faculty of Medicine | 130  |
| <b>Iran</b>      | 1 | Rezaei, N.       | 75 | Medicine                                     | 2655 | Tehran University of Medical Sciences                         | 885  |
|                  | 2 | Tabarsi, P.      | 40 | Biochemistry, Genetics and Molecular Biology | 502  | Shahid Beheshti University of Medical Sciences                | 665  |
|                  | 3 | Zali, A.         | 28 | Immunology and Microbiology                  | 485  | Iran University of Medical Sciences                           | 490  |
|                  | 4 | Jamaati, H.      | 27 | Pharmacology, Toxicology and Pharmaceutics   | 330  | Shiraz University of Medical Sciences                         | 348  |
|                  | 5 | Marjani, M.      | 22 | Social Sciences                              | 219  | Tabriz University of Medical Sciences                         | 241  |
| <b>Ud i Arab</b> | 1 | Rabaan, A.A.     | 40 | Medicine                                     | 1534 | King Saud University  | 632  |
|                  | 2 | Al-Tawfiq,       | 36 | Computer Science                             | 424  | King Abdulaziz University                                     | 484  |

|                     |   |                       |    |  |      |  |     |
|---------------------|---|-----------------------|----|--|------|--|-----|
|                     |   | J.A.                  |    |  |      |  |     |
|                     | 3 | Memish, Z.A.          | 34 | Biochemistry, Genetics and Molecular Biology | 369  | Imam Abdulrahman Bin Faisal university                 | 229 |
|                     | 4 | Dhama, K.             | 33 | Engineering                                  | 298  | King Saud bin Abdulaziz University for Health Sciences | 220 |
|                     | 5 | Halwani, R.           | 28 | Social Sciences                              | 289  | Taif University  | 197 |
| <b>Japan</b>        | 1 | Ohmagari, N.          | 47 | Medicine                                     | 1770 | The University of Tokyo                                | 270 |
|                     | 2 | Suzuki, T.            | 27 | Biochemistry, Genetics and Molecular Biology | 400  | Kyoto University                                       | 152 |
|                     | 3 | Kinoshita, N.         | 26 | Social Sciences                              | 319  | Hokkaido University                                    | 123 |
|                     | 4 | Nishiura, H.          | 26 | Environmental Science                        | 275  | Keio University  | 96  |
|                     | 5 | Yoneoka, D.           | 22 | Immunology and Microbiology                  | 264  | National Center for Global Health and Medicine         | 93  |
| <b>Netherlands</b>  | 1 | Netea, M.G.           | 37 | Medicine                                     | 1820 | Erasmus MC   | 341 |
|                     | 2 | Haagmans, B.L.        | 25 | Social Sciences                              | 431  | Universiteit van Amsterdam                             | 335 |
|                     | 3 | van Gils, M.J.        | 22 | Biochemistry, Genetics and Molecular Biology | 315  | Universiteit Utrecht                                   | 272 |
|                     | 4 | Koopmans, M.P.G.      | 21 | Immunology and Microbiology                  | 254  | Universiteit Maastricht                                | 262 |
|                     | 5 | van de Veerdonk, F.L. | 21 | Environmental Science                        | 196  | Amsterdam UMC - University of Amsterdam                | 258 |
| <b>Switzerland</b>  | 1 | Kaiser, L.            | 38 | Medicine                                     | 1825 | University of Zurich                                   | 388 |
|                     | 2 | Akdis, C.A.           | 27 | Biochemistry, Genetics and Molecular Biology | 356  | University of Bern                                     | 328 |
|                     | 3 | Eckerle, I.           | 26 | Immunology and Microbiology                  | 258  | Hôpitaux Universitaires de Genève                      | 275 |
|                     | 4 | Guessous, I.          | 22 | Social Sciences                              | 242  | Université de Genève                                   | 260 |
|                     | 5 | Agache, I.            | 19 | Environmental Science                        | 159  | Universitat Basel                                      | 246 |
| <b>South Korea</b>  | 1 | Peck, K.R.            | 27 | Agricultural and Biological Sciences         | 48   | Seoul National University                              | 201 |
|                     | 2 | Kim, Y.J.             | 23 | Arts and Humanities                          | 44   | Seoul National University College of Medicine          | 164 |
|                     | 3 | Kim, S.H.             | 21 | Biochemistry, Genetics and Molecular Biology | 281  | Yonsei University                                      | 132 |
|                     | 4 | Bhattacharya, M.      | 20 | Business, Management and Accounting          | 120  | Yonsei University College of Medicine                  | 129 |
|                     | 5 | Chakraborty, C.       | 20 | Chemical Engineering                         | 79   | University of Ulsan College of Medicine                | 118 |
| <b>Pakistan</b>     | 1 | Shah, K.              | 33 | Medicine                                     | 1018 | The Aga Khan University                                | 153 |
|                     | 2 | Ullah, I.             | 21 | Social Sciences                              | 217  | University of the Punjab                               | 109 |
|                     | 3 | Bilal, M.             | 17 | Biochemistry, Genetics and Molecular Biology | 201  | Quaid-i-Azam University                                | 98  |
|                     | 4 | Ahmad, S.             | 16 | Computer Science                             | 194  | Dow University of Health Sciences Pakistan             | 88  |
|                     | 5 | Abdeljawad, T.        | 15 | Environmental Science                        | 173  | The Aga Khan University Hospital                       | 84  |
| <b>South Africa</b> | 1 | Wysong, C.S.          | 23 | Medicine                                     | 1017 | University of Cape Town                                | 370 |
|                     | 2 | Giovanetti, M.        | 16 | Social Sciences                              | 511  | University of the Witwatersrand, Johannesburg          | 300 |

|                  |   |                  |    |  |      |  |     |
|------------------|---|------------------|----|--|------|--|-----|
|                  | 3 | Nachege, J.B.    | 16 | Biochemistry, Genetics and Molecular Biology | 210  | University of KwaZulu-Natal              | 292 |
|                  | 4 | Zumla, A.        | 16 | Business, Management and Accounting          | 160  | Stellenbosch University                  | 284 |
|                  | 5 | de Oliveira, T.  | 16 | Arts and Humanities                          | 133  | University of Pretoria                   | 230 |
| <b>Poland</b>    | 1 | Agache, I.       | 20 | Medicine                                     | 1125 | Medical University of Warsaw             | 216 |
|                  | 2 | Banach, M.       | 20 | Social Sciences                              | 266  | Wroclaw Medical University               | 171 |
|                  | 3 | Wierzba, W.      | 20 | Environmental Science                        | 265  | Jagiellonian University Medical College  | 145 |
|                  | 4 | Jutel, M.        | 17 | Biochemistry, Genetics and Molecular Biology | 226  | Poznan University of Medical Sciences    | 145 |
|                  | 5 | Klimek, L.       | 16 | Immunology and Microbiology                  | 145  | Slaski Uniwersytet Medyczny w Katowicach | 142 |
| <b>Indonesia</b> | 1 | Pranata, R.      | 49 | Medicine                                     | 801  | Universitas Indonesia                    | 248 |
|                  | 2 | Harapan, H.      | 41 | Social Sciences                              | 493  | Universitas Airlangga                    | 180 |
|                  | 3 | Lim, M.A.        | 29 | Pharmacology, Toxicology and Pharmaceutics   | 189  | Universitas Padjadjaran                  | 142 |
|                  | 4 | Huang, I.        | 27 | Business, Management and Accounting          | 183  | Universitas Gadjah Mada                  | 115 |
|                  | 5 | Kurniawan, A.    | 23 | Biochemistry, Genetics and Molecular Biology | 155  | Universitas Pelita Harapan               | 87  |
| <b>Egypt</b>     | 1 | Mostafa, A.      | 20 | Medicine                                     | 1021 | Cairo University                         | 410 |
|                  | 2 | Batiha, G.E.S.   | 17 | Biochemistry, Genetics and Molecular Biology | 267  | Mansoura University                      | 190 |
|                  | 3 | Abdel-Daim, M.M. | 16 | Pharmacology, Toxicology and Pharmaceutics   | 190  | Alexandria University                    | 182 |
|                  | 4 | Hassanien, A.E.  | 16 | Computer Science                             | 177  | Ain Shams University                     | 171 |
|                  | 5 | Hetta, H.F.      | 16 | Immunology and Microbiology                  | 164  | Zagazig University                       | 146 |
| <b>Belgium</b>   | 1 | Lechien, J.R.    | 51 | Medicine                                     | 1281 | KU Leuven                                | 397 |
|                  | 2 | Saussez, S.      | 41 | Biochemistry, Genetics and Molecular Biology | 254  | Universiteit Gent                        | 246 |
|                  | 3 | Neyts, J.        | 29 | Immunology and Microbiology                  | 210  | Universiteit Antwerpen                   | 241 |
|                  | 4 | Colebunders, R.  | 26 | Social Sciences                              | 186  | Université Libre de Bruxelles            | 238 |
|                  | 5 | Vaira, L.A.      | 26 | Environmental Science                        | 123  | Université Catholique de Louvain         | 173 |
| <b>Sweden</b>    | 1 | Pakpour, A.H.    | 27 | Medicine                                     | 1088 | Karolinska Institutet                    | 568 |
|                  | 2 | Lin, C.Y.        | 24 | Social Sciences                              | 273  | Karolinska Universitetssjukhuset         | 265 |
|                  | 3 | Griffiths, M.D.  | 22 | Biochemistry, Genetics and Molecular Biology | 236  | Uppsala Universitet                      | 219 |
|                  | 4 | Frithiof, R.     | 20 | Immunology and Microbiology                  | 191  | Lunds Universitet                        | 210 |
|                  | 5 | Hultström, M.    | 19 | Environmental Science                        | 161  | Göteborgs Universitet                    | 185 |

Table 21 highlights the leading authors, subject areas, and institutions in COVID-19 research of the remaining 15 countries namely Brazil, Turkey, Iran, Saudi Arabia, Japan, Netherlands, Switzerland, South Korea, Pakistan, South Africa, Poland, Indonesia, Egypt, Belgium, and Sweden. We can see that the subject area ‘medicine’ has the highest number of publications of all countries which is quite natural as the entire world is working hard to overcome the health crisis by seeking medicine or vaccine as early as feasible. In terms of paper publication, N. Ohmagari of Iran holds first place followed by J.R. Lechien of Belgium contributing 75 and 51 papers respectively. During this short time R. Pranata of Indonesia produced 49 papers securing the third position, and the remaining authors from those 15 countries contributed papers ranging from 16 to 40 in number. Universidade de São Paulo of Brazil put a good impression on carrying on the COVID-19 research. The institute submitted a total of 1074 papers. In terms of paper publication, the Tehran University of Medical Sciences is not also far behind. The institute developed 885 papers in this area. Among the 15 countries, these two institutes came in first and second place, respectively.

#### 4.12. Keyword analysis of top five countries

**Table 22:** List of Keywords of top five countries according to the published papers

| R  | USA                      |       | UK                       |      | CHINA                    |       | ITALY                    |      | INDIA   |      |
|----|--------------------------|-------|--------------------------|------|--------------------------|-------|--------------------------|------|---|------|
|    | Keyword                  | TP    | Keyword                  | TP   | Keyword                  | TP    | Keyword                  | TP   | Keyword   | TP   |
| 1  | COVID-19                 | 26343 | COVID-19                 | 9921 | COVID-19                 | 10161 | COVID-19                 | 8142 | COVID-19  | 6689 |
| 2  | Human                    | 24283 | Human                    | 8705 | Human                    | 9260  | Human                    | 7679 | Human   | 5014 |
| 3  | Humans                   | 20898 | Humans                   | 7223 | Humans                   | 7690  | Humans                   | 6155 | Coronavirus Disease 2019                        | 3819 |
| 4  | Coronavirus Disease 2019 | 15726 | Coronavirus Disease 2019 | 5799 | Coronavirus Disease 2019 | 6783  | Coronavirus Disease 2019 | 5734 | Humans  | 3319 |
| 5  | Pandemic                 | 14942 | Pandemic                 | 5709 | Article                  | 5684  | Pandemic                 | 4701 | Pandemic  | 3297 |
| 6  | SARS-CoV-2               | 13366 | Article                  | 4707 | SARS-CoV-2               | 5167  | Article                  | 4527 | SARS-CoV-2                                      | 2995 |
| 7  | Article                  | 13091 | SARS-CoV-2               | 4591 | Pandemic                 | 4939  | SARS-CoV-2               | 4425 | Article   | 2691 |
| 8  | Pandemics                | 11272 | Pandemics                | 4033 | Female                   | 4730  | Pandemics                | 3518 | Pandemics                                       | 1774 |
| 9  | Female                   | 9279  | Female                   | 3354 | Male                     | 4667  | Female                   | 3451 | India   | 1718 |
| 10 | Male                     | 8877  | Male                     | 3213 | China                    | 4517  | Male                     | 3429 | Severe Acute Respiratory Syndrome Coronavirus 2 | 1599 |
| 11 | Adult                    | 8127  | Adult                    | 2896 | Pandemics                | 4234  | Adult                    | 2830 | Female  | 1287 |
| 12 | Priority Journal         | 6825  | Virus Pneumonia          | 2269 | Adult                    | 4186  | Italy                    | 2769 | Review  | 1277 |
| 13 | Virus Pneumonia          | 6734  | Priority Journal         | 2251 | Virus Pneumonia          | 3330  | Virus Pneumonia          | 2447 | Male  | 1245 |



|    |                                   |      |   |      |   |      |   |      |                        |      |
|----|-----------------------------------|------|---|------|---|------|---|------|------------------------|------|
| 14 | Coronavirus Infection             | 6622 | Coronavirus Infection                           | 2230 | Coronavirus Infection                           | 3155 | Pneumonia, Viral                                | 2309 | Priority Journal       | 1216 |
| 15 | Coronavirus Infections            | 6602 | Coronavirus Infections                          | 2224 | Pneumonia, Viral                                | 3149 | Coronavirus Infections                          | 2282 | Adult                  | 1164 |
| 16 | Pneumonia, Viral                  | 6528 | Pneumonia, Viral                                | 2190 | Coronavirus Infections                          | 3146 | Coronavirus Infection                           | 2281 | Nonhuman               | 1159 |
| 17 | Severe Acute Respiratory Syndrome | 5512 | Middle Aged                                     | 1909 | Middle Aged                                     | 3082 | Aged  | 2252 | Coronavirus            | 1143 |
| 18 | Betacoronavirus                   | 5343 | Epidemiology                                    | 1903 | Betacoronavirus                                 | 2710 | Severe Acute Respiratory Syndrome Coronavirus 2 | 2202 | Virus Pneumonia        | 1093 |
| 19 | Middle Aged                       | 5336 | Aged  | 1871 | Severe Acute Respiratory Syndrome Coronavirus 2 | 2688 | Middle Aged                                     | 2122 | Coronavirus Infection  | 1070 |
| 20 | Aged                              | 4945 | Betacoronavirus                                 | 1827 | Aged  | 2560 | Priority Journal                                | 1987 | Coronavirus Infections | 1054 |
| 21 | Epidemiology                      | 4860 | United Kingdom                                  | 1668 | Controlled Study                                | 2538 | Betacoronavirus                                 | 1950 | Pneumonia, Viral       | 1023 |
| 22 | United States                     | 4758 | Major Clinical Study                            | 1642 | Major Clinical Study                            | 2469 | Major Clinical Study                            | 1647 | Betacoronavirus        | 932  |
| 23 | Controlled Study                  | 4488 | Severe Acute Respiratory Syndrome Coronavirus 2 | 1642 | Priority Journal                                | 2378 | Controlled Study                                | 1410 | Virology               | 795  |
| 24 | Procedures                        | 4411 | Controlled Study                                | 1615 | Virology  | 2107 | Virology  | 1400 | Controlled Study       | 707  |
| 25 | Virology                          | 4187 | Coronavirus                                     | 1494 | Retrospective Study                             | 2046 | Epidemiology                                    | 1342 | Epidemiology           | 695  |

According to the number of articles published, in Table 22 we have considered 25 keywords from the top five countries namely the USA, UK, China, Italy, and India, and sorted the keywords in descending order. The keyword COVID-19 appears to be near the top of the search results in each of the countries. It is quite natural because all the research papers are focussing here on different aspects of the COVID-19 virus. It is 26343 in the USA. Then proceed to China, U.K., Italy, and India in that order. Keywords like *human*, *humans*, *coronavirus disease 2019*, *SARSCOV2*, *pandemic*, and *male and female* have been used frequently. Since the clinical trials have been conducted on people of various ages, the keywords *aged*, and *middle aged* has been used frequently. In terms of the number of publications, the keyword *virology* has appeared 4187 times in the United States, however it is not on the list in the United Kingdom. The keyword *COVID-19* ranks first in all five countries, with a significant difference in number between the United States and the remaining four. The differences between the United States and the United Kingdom, China, Italy, and India are 16422, 16182, 18201, and 19654, respectively. The keyword *retrospective study* has been added to the Chinese keyword list once more,

however, it is not included in the list of 25 keywords from the other four nations. The Table 22 reveals that the keywords *review* and *non-human* are only found in India's list of keywords. Again, it is observed that in the Indian keyword list, the term *epidemiology* appears only 695 times and is placed last in the Table 22, whereas in the United States, the term *virology* appears at the final position and has a TP of 4187. Keyword, *Major Clinical Study* is not on the list for the United States or India, but it is on the list for the remaining three countries: the United Kingdom, China, and Italy. The Table 22 also shows that almost all of the keywords have significant numerical differences between the United States and the remaining four other countries.

## **5. Discussion and analysis of important findings**

*i)* USA, U.K., China, Italy, and India have all made a significant contribution to COVID-19 research. Research on COVID-19 is being conducted in a variety of directions, which is a good sign of interdisciplinary research. In China it is observed infected patients have a history of going to or working local seafood markets in Wuhan city. It is observed three authors of China have published three papers that have more than 10000 citations within a very short span of time. It has been observed by some authors that the quality of the environment has significantly improved due to the long duration of lockdown around the world which is a positive side of lockdown.

*ii)* We have made an important observation. *The Lancet* and *New England Journal of Medicine*, according to the Scopus database, are the pioneering journal in terms of citation ensuring their excellence. *The Lancet* remains in the highest position while *New England Journal of Medicine* secures the second position. Kappa et. al., (2021) used the web of science database to observe that *New England Journal of Medicine* and *The Lancet* occupies the first and second position respectively. Therefore, it can be inferred that the journals *The Lancet*, and *New England Journal of Medicine* are mostly preferred and high-quality journals to the researchers irrespective of Scopus or web of science database.

### ***iii)* Leading collaborative research works:**

Leading articles of the top ten countries, we see that some articles are simultaneously enlisted in the list of the leading articles of several countries. Bikdeli et al., (2020) published their paper in

the *Journal of American College of Cardiology* that received 1224 citations. This article enlisted in the lists of the leading articles of five countries: Italy, Spain, Germany, Australia, and France. Grein et al., (2020) produced their paper in the famous journal *New England Journal of Medicine* gaining 1344 citations. This work is listed in the lists of the leading articles of four different countries like Italy, Canada, Spain, and France. Lechien et al., (2020) wrote their paper in the *European Archives of Oto-Rhino-Laryngology* that received 1068 citations. They are simultaneously listed in the four countries namely Italy, Canada, Spain, and France. Bavel et al., (2020) published their paper in *Nature Human Behaviour* receiving 1154 citations. They are listed in two different countries: Canada, and Australia. Holms et al., (2020) submitted their paper in *The Lancet Psychiatry* that received a total of 1617 citations. It is concurrently mentioned in the lists of the leading articles of two countries the U.K., and Australia. Paper developed by Wu, F. et al., (2020) is published *Nature* having 3815 citations. It is concurrently mentioned in the lists of the leading articles of two countries China, and Australia. Polack et al., (2020) produced their paper in *New England Journal of Medicine* with 2180 citations. It is listed in both U.K. and Germany. Beigel et al., (2020) published a manuscript in the prestigious *New England Journal of Medicine*, which received 2186 citations. They are concurrently listed in three different countries namely the U.K., Spain, and Germany. Wölfel et al., (2020) submitted their article in 'Nature' that gained 2685 citations. It is simultaneously mentioned in two countries U.K., and Germany. With citations 4905, Lu et al., (2020) published their article in the prestigious medical journal *The Lancet*. China, and Australia are the two countries where it is listed. Cao et al., (2020) wrote their manuscript in *New England Journal of Medicine* which got 2668 citations. They are associated with two countries: the U.K., and China. Mao et al., (2020) has produced their paper in *JAMA Neurology* that received 2655 citations. They are listed in two countries at the same time: the USA, and China.

#### **iv) Top collaborating authors**

Some authors appeared simultaneously in the list of leading authors in COVID-19 research of 25 countries. Italian professor Giuseppe Lippi from the University of Verona is leading simultaneously in three countries: USA, Italy, and Australia with 63, 87, and 25 publications respectively. Professor Giuseppe Lippi has a total of 87 publications in COVID-19 related research and among these publications, he collaborates 63 with American authors and 25 with

Australian authors. Saudi Arabian author Ali A. Rabaan is leading in two different countries: India, and Saudi Arabia. Both Germany and Netherlands enlisted M.G. Netea, whereas J. Bousquetis listed in Germany, and France. Again, Dyer is attached with France as well as Canada where, L. Jacob is also enlisted for both France and Spain. Both the USA and Saudi Arabia contain the author J.A. Ai-Tawfiq. The Indian author K. Dhama is included in the list of Saudi Arabia also. R. Halwani is associated with Canada, and Saudi Arabia while L. Agacheis linked to Spain, Switzerland, and Poland. Again, M. Giovanetti is listed in two different countries namely South Africa, and Brazil where L. Klimek is linked to Germany, and Poland. French and Belgium are related with S. Saussez where M. D. Griffiths is listed in both the United Kingdom and Sweden. J.R. Lechien. is known for his work in France, Spain, and Belgium where A. Zumla is connected with the United Kingdom, and South Africa. Both the countries the United Kingdom, and Spain enlisted the author L. Smith where Z.A. Memish, has ties to the United States and Saudi Arabia. M. Bilal is linked to China along with Italy and both the USA and Italy include B.M. Henry.

#### **v) Different insights of using the drug remdesivir**

Jin et al., (2020) were unable to reach a definite conclusion about the efficacy of remdesivir. They guessed that early application of remdesivir may be effective but they are in doubt about the outcomes of late treatment. They think that more exploration is required in this matter. Grein et al., (2020) concluded that this drug may take an effective role for severe patients. After careful observations of hospitalized patients admitted to ten hospitals, Wang et al., (2020) inferred that the remdesivir drug has no significant effect on the covid infected patients. Wiersinga et al., (2000) observed that remdesivir is able in lowering the recovery time for non-severe patients. Beigel et al., (2020) took into account of 1062 patients among which 541 are given remdesivir while the remaining 521 were applied placebo. It is observed that patients who received remdesivir recovered faster than those who are treated with a placebo. The drug is also helpful in reducing respiratory tract infections.

#### **vi) Glimpse of mathematics in COVID-19 related research**

Here we highlight some papers which contributes mathematical implications relevant to the topic. Aydin and Tirkolae (2021) discussed the country level calibration and prediction based

on some well-known models like logistic model, exponential model, Gompertz model, SIR model and SEIR model using real data from different countries. They calculated goodness of fit and compared the efficacy of the above-mentioned models.

In the logistic model the total number of infected is calculated by the formula

$$I_t^{(1)} = \frac{c}{1 + e^{-\frac{t-b}{a}}} \text{ where } a, b, \text{ and } c \text{ are the infection speed, inflection point (the}$$

point at which the maximum increase in the number of infected occurs), and the estimated number of infected once the pandemic ends respectively.

$$\text{Now, } I''(t) = \frac{c\gamma(1-\gamma^2)}{a^2(1+\gamma)^4} \text{ where } \gamma(t) = e^{-(t-b)/a}$$

$I''(t)=0$  gives  $\gamma=1$  which is possible only when  $t=b$  or  $t \rightarrow \infty$  and  $b$  is said to be point of inflection. When  $t \rightarrow \infty$ ,  $I_t = c$  giving horizontal asymptote and the flatten level of  $I_t$ .

$$\text{That means } I_t' = \frac{c\gamma}{a(1+\gamma)^2} = 0 \Rightarrow t \rightarrow \infty$$

In the exponential model, the total number of infected is calculated as  $I_t^{(2)} = a \cdot e^{b(t-c)}$  where  $a$ ,  $b$ ,  $c$  are the initial number of infected growth rate, and starting date of infection. But this model does not converge when it becomes larger.

Next, they consider ‘Gompertz Growth Model’. The number of infections is calculated by the formula,  $I_t^{(2)} = a \cdot e^{-b(t-c)}$  where  $a$ ,  $b$ ,  $c$  are the upper bounds of total number of infected, the growth rate, and the location parameter respectively. The maximum rate of increase in the number of infected occurs at  $t = \frac{\ln b}{c}$  obtained from the differential equation  $I'' = Ib^2c^2e^{-ct} (e^{-ct} - \frac{1}{b}) = 0$

For calibration they used Python SciPy along with the Scikit Library.

In the SIR model, the systems of quadratic equations are

$$\begin{aligned}dS_t &= -\beta S_t I_t^{(4)} dt \\dI_t^{(4)} &= (\beta S_t - \gamma) I_t^{(4)} dt \\dR_t &= \gamma I_t^{(4)} dt\end{aligned}$$

Where  $\beta$  and  $\gamma$  are the transmission and recovery rates respectively, and  $\lim_{t \rightarrow \infty} S_t$ ,  $\lim_{t \rightarrow \infty} I_t$  and  $\lim_{t \rightarrow \infty} R_t$  exist.

SEIR model is the extension of SIR model. In this model, the system of differential equations are given by

$$\begin{aligned}dS_t &= -\beta S_t I_t^{(5)} dt \\dE_t &= (\beta S_t I_t^{(5)} - \theta E_t) dt \\dI_t^{(5)} &= (\theta E_t - \gamma I_t^{(5)}) dt \\dR_t &= \gamma I_t^{(5)} dt\end{aligned}$$

Where  $\beta$  and  $\gamma$  are the transmission and the recovery rates respectively, and  $\theta$  is the incubation rate.

To examine the production, distribution, and recycling of face masks during the COVID-19 pandemic, a mathematical model of a sustainable Closed Loop Supply Chain Network (CLSCN) has been developed by Tirkolace et al. (2021). A multi-objective **Mixed Integer Linear Programming** (MILP) has been proposed to address the allocation, supply, production, distribution, collection, quarantine, recycling, reuse, and disposal within the proposed networks. They considered two types of supply chain networks-forward supply chain and reverse supply chain. Forward supply chain networks include different levels of suppliers, factories, distribution centers, customer centers, and reverse supply chain network includes recycling centers, collection centers, quarantine centers, and disposal centers. The basic objectives were to minimize human risks as much as possible using sustainable face masks along with the minimization of other cost which includes establishment cost, transportation cost and employment cost, and total environmental pollution within CLSCN keeping in the mind the social, economic and environmental impact. They proposed two multi-objective meta heuristic algorithm of **Multi-Objective Grey Wolfe Optimization (MOGWO)**, and NAGA-II to

overcome the complexity of the problem and validated the outcome of the proposed model by using real case study in Tehran of Iran. It is almost impossible to determine the future trends of the COVID-19 virus due to its presence of some stochastic parameters. Khalilpourazari et al (2021) applied a new algorithm **named Gradient -based Grey Wolfe Optimizer (GGWO)** in the prediction of future trends of SARS-CoV-2 and demanded that the had proved its efficacy in the United States. They also hope that the proposed method will enable the researchers to solve the complex function in future. Like Particle Swarm optimization (PSO), the GGWO Starts with initial population and next find the dominant members of the wolves. In this way the wolves update their position in the solution space near the target. Mondal and Roy (2021) presented a sustainable opened and closed supply chain (SOCLSC) planning to manage supply among production centers and various hospitals during the sudden outbreak of COVID-19 pandemic. A **multi objective mixed integer programming (MOMIP)** describing a two-stage SOCLSC in an uncertain environment is applied to solve the proposed model. The primary objective was to minimize the total cost (production cost, holding cost, and distribution cost), total time, and the weighted backlog amount as well as to maximize the social impact by increasing job opportunities in production system, proper handling of produced items, and optimal distribution of the available items. To deal with the **uncertainty** in different scenarios, they used **Robust Optimization (RO)** approach, and applied **Augmented Weighted Tchebycheff Method (AWTM)** to solve the model.

## 6. Conclusions

This bibliometric analysis of COVID-19 was designed with great care. Through this study, we try to depict a summary of global research progress on the current and burning issue. That is, we are aware of the research position to solve the present global health calamity. Here we consider twenty (25) leading countries across six continents that are actively involved in COVID-19 research. We have included different parameters to frame our study like TP, H-index, citation threshold, leading authors, subject area, institutions in terms of TP of those countries, and most commonly used keywords with TP of the top five countries to construct our analysis.

After careful study, we see that the USA is the leading country followed by U.K. and China but with respect to H-index China remains in a better position. The keyword *COVID-19* is mostly used, and the highest numbers of papers have been developed in the area of *medicine*. The

Harvard Medical School of the U.K. contributed the highest number of papers followed by the University of Toronto of Canada and Huazhong University of Science and Technology respectively. Professor K Dhama India of the published highest number of papers while C. Huang of China received the highest number of citations followed by W. Guan of the same country. It is also seen that *The Lancet*, *New England Journal of Medicine*, *Journal of American Medical Association (JAMA)*, *The Lancet Psychiatry*, and *Nature* are the pioneering journals attractive to the researchers for publication of their valuable work. All these journals are working hard to bring the essence of research to the world as soon as feasible.

We may suggest the following research fields that may be promising in near future. (i) Use of AI in research COVID-19 research. (ii) Use of data analysis to find several factors behind the infection. More exploration is required to find whether it is event-specific or not. (iii) Emphasis should be given to Interdisciplinary research, which may disclose/reveal a new perspective. (iv) Effects of prolonged lockdown on the environment, education, and economy. (v) Impact of COVID-19 in the change of human development index. (vi) how does the situation affect the supply chain logistics?

This work has following major limitation. A document will be considered for a country if one or more authors used affiliation of that country. Suppose a document has N authors from M different countries then it will be considered in the account of all M countries associated with its authors. Thus, a document may be possible to display in the account of more than one country. We have used Scopus database and results are based on the outcome of the database.

## References

Ackermann, M., Verleden, S. E., Kuehnel, M., et al., (2020). Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. *New England Journal of Medicine*, 383(2), 120-128. doi:10.1056/NEJMoa2015432.



- Aydin, N. S., & Tirkolaei, E. B. (2022). Modelling and Predicting The Growth Dynamics Of Covid-19 Pandemic: A Comparative Study Including Turkey. *Journal of Turkish Operations Management*, 6(1), 943-954.
- Babaei Tirkolaei, E., & Aydın, N. S. (2021). A sustainable medical waste collection and transportation model for pandemics. *Waste Management & Research*, 39(1), 34-44.
- Bavel, J. J. V., Baicker, K., Boggio, P. S., et al., (2020). Using social and behavioural science to support COVID-19 pandemic response. *Nature Human Behaviour*, 4(5), 460-471. doi:10.1038/s41562-020-0884-z
- Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., . . . Lane, H. C. (2020). Remdesivir for the treatment of COVID-19 — final report. *New England Journal of Medicine*, 383(19), 1813-1826. doi:10.1056/NEJMoa2007764
- Bikdeli, B., Madhavan, M. V., Jimenez, D., et al., (2020). COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. *Journal of the American College of Cardiology*, 75(23), 2950-2973. doi: 10.1016/j.jacc.2020.04.031
- Cao, B., Wang, Y., Wen, D., et al., (2020). A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. *New England Journal of Medicine*, 382(19), 1787-1799. doi:10.1056/NEJMoa2001282
- Chan, J. F., Yuan, S., Kok, K. et al., (2020). A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. *The Lancet*, 395(10223), 514-523. doi:10.1016/S0140-6736(20)30154-9
- Chen, N., Zhou, M., Dong, X., et al., (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. *The Lancet*, 395(10223), 507-513. doi:10.1016/S0140-6736(20)30211-7
- Chinazzi, M., Davis, J. T., Ajelli, M., et al., (2020). The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. *Science*, 368(6489), 395-400. doi:10.1126/science.aba9757
- Chu, D. K., Akl, E. A., Duda, S., et al., (2020). Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: A systematic review and meta-analysis. *The Lancet*, 395(10242), 1973-1987. doi:10.1016/S0140-6736(20)31142-9
- Emanuel, E. J., Persad, G., Upshur, R., et al., (2020). Fair allocation of scarce medical resources in the time of COVID-19. *New England Journal of Medicine*, 382(21), 2049-2055. doi:10.1056/NEJMs2005114

- Gautret, P., Lagier, J., Parola, P., et al., (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. *International Journal of Antimicrobial Agents*, 56(1) doi:10.1016/j.ijantimicag.2020.105949
- Ghadir, A. H., Vandchali, H. R., Fallah, M., & Tirkolae, E. B. (2022). Evaluating the impacts of COVID-19 outbreak on supply chain risks by modified failure mode and effects analysis: a case study in an automotive company. *Annals of Operations Research*, 1-31.
- Gordon, D. E., Jang, G. M., Bouhaddou, M., et al., (2020). A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature*, 583(7816), 459-468. doi:10.1038/s41586-020-2286-9
- Grasselli, G., Zangrillo, A., Zanella, A., et al., (2020). Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. *JAMA - Journal of the American Medical Association*, 323(16), 1574-1581. doi:10.1001/jama.2020.5394
- Grein, J., Ohmagari, N., Shin, D., et al., (2020). Compassionate use of remdesivir for patients with severe COVID-19. *New England Journal of Medicine*, 382(24), 2327-2336. doi:10.1056/NEJMoa2007016
- Guan, W., Ni, Z., Hu, Y., et al., (2020). Clinical characteristics of coronavirus disease 2019 in China. *New England Journal of Medicine*, 382(18), 1708-1720. doi:10.1056/NEJMoa2002032
- Helms, J., Tacquard, C., Severac, F., et al., (2020). High risk of thrombosis in patients with severe SARS-CoV-2 infection: A multicenter prospective cohort study. *Intensive Care Medicine*, 46(6), 1089-1098. doi:10.1007/s00134-020-06062-x
- Hoffmann, M., Kleine-Weber, H., Schroeder, S., et al., (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell*, 181(2), 271-280.e8. doi: 10.1016/j.cell.2020.02.052
- Holmes, E. A., O'Connor, R. C., Perry, V. H., et al., (2020). Multidisciplinary research priorities for the COVID-19 pandemic: A call for action for mental health science. *The Lancet Psychiatry*, 7(6), 547-560. doi:10.1016/S2215-0366(20)30168-1
- Holshue, M. L., DeBolt, C., Lindquist, S., et al., (2020). First case of 2019 novel coronavirus in the United States. *New England Journal of Medicine*, 382(10), 929-936. doi:10.1056/NEJMoa2001191
- Hossain, M. M., Sarwar, S. A., McKyer, E. L. J., & Ma, P. (2020). Applications of artificial intelligence technologies in COVID-19 research: A bibliometric study. *Preprints 2020*, 2020060161 (doi: 10.20944/preprints202006.0161.v1)

- Huang, C., Wang, Y., Li, X., et al., (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*, 395(10223), 497-506. doi:10.1016/S0140-6736(20)30183-5
- Jin, Z., Du, X., Xu, Y., et al., (2020). Structure of mpro from SARS-CoV-2 and discovery of its inhibitors. *Nature*, 582(7811), 289-293. doi:10.1038/s41586-020-2223-y
- Kampf, G., Todt, D., Pfaender, S., & Steinmann, E. (2020). Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. *Journal of Hospital Infection*, 104(3), 246-251. doi: 10.1016/j.jhin.2020.01.022
- Khalilpourazari, S., Doulabi, H. H., Çiftçioğlu, A. Ö., & Weber, G. W. (2021). Gradient-based grey wolf optimizer with Gaussian walk: Application in modelling and prediction of the COVID-19 pandemic. *Expert Systems with Applications*, 177, 114920.
- Kappi, M., Sab, M. C., Biradar, B. S., & Bagalkoti, V. T. (2021). Bibliometric Study of World COVID-19 Publication Output. *Shanlax International Journal of Arts, Science and Humanities*, 8(3), 86-95.
- Lechien, J. R., Chiesa-Estomba, C. M., De Siaty, D. R., et al., (2020). Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): A multicenter European study. *European Archives of Oto-Rhino-Laryngology*, 277(8), 2251-2261. doi:10.1007/s00405-020-05965-1
- Liu, Y., Gayle, A. A., Wilder-Smith, A., & Rocklöv, J. (2020). The reproductive number of COVID-19 is higher compared to SARS coronavirus. *Journal of Travel Medicine*, 27(2) doi:10.1093/jtm/taaa021
- Lu, R., Zhao, X., Li, J., et al., (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. *The Lancet*, 395(10224), 565-574. doi:10.1016/S0140-6736(20)30251-8
- Mao, L., Jin, H., Wang, M., et al., (2020). Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. *JAMA Neurology*, 77(6), 683-690. doi:10.1001/jamaneurol.2020.1127
- Mondal, A., & Roy, S. K. (2021). Multi-objective sustainable opened-and closed-loop supply chain under mixed uncertainty during COVID-19 pandemic situation. *Computers & Industrial Engineering*, 159, 107453.
- Nicola, M., Alsafi, Z., Sohrabi, C., et al., (2020). The socio-economic implications of the coronavirus pandemic (COVID-19): A review. *International Journal of Surgery*, 78, 185-193. doi: 10.1016/j.ijssu.2020.04.018

- Polack, F. P., Thomas, S. J., Kitchin, N., et al., (2020). Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. *New England Journal of Medicine*, 383(27), 2603-2615. doi:10.1056/NEJMoa2034577
- Rajkumar, R. P. (2020). COVID-19 and mental health: A review of the existing literature. *Asian Journal of Psychiatry*, 52 doi: 10.1016/j.ajp.2020.102066
- Remuzzi, A., & Remuzzi, G. (2020). COVID-19 and italy: What next? *The Lancet*, 395(10231), 1225-1228. doi:10.1016/S0140-6736(20)30627-9
- Richardson, S., Hirsch, J. S., Narasimhan, M., et al., (2020). Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. *JAMA - Journal of the American Medical Association*, 323(20), 2052-2059. doi:10.1001/jama.2020.6775
- Rodriguez-Morales, A. J., Cardona-Ospina, J. A., Gutiérrez-Ocampo, E., et al., (2020). Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. *Travel Medicine and Infectious Disease*, 34, 101623.
- Rothan, H. A., & Byrareddy, S. N. (2020). The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *Journal of Autoimmunity*, 109 doi: 10.1016/j.jaut.2020.102433
- Singhal, T. (2020). A review of coronavirus disease-2019 (COVID-19). *Indian Journal of Pediatrics*, 87(4), 281-286. doi:10.1007/s12098-020-03263-6
- Sohrabi, C., Alsafi, Z., O'Neill, N., et al., (2020). World health organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). *International Journal of Surgery*, 76, 71-76. doi: 10.1016/j.ijso.2020.02.034
- Su, M., Xu, S., & Weng, J. (2021). A bibliometric study of COVID-19 researches in Web of Science. *Pharmacological Research*, 169, 105664.
- Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020). The trinity of COVID-19: Immunity, inflammation and intervention. *Nature Reviews Immunology*, 20(6), 363-374. doi:10.1038/s41577-020-0311-8
- Tirkolaee, E. B., Goli, A., Ghasemi, P., & Goodarzian, F. (2022). Designing a sustainable closed-loop supply chain network of face masks during the COVID-19 pandemic: Pareto-based algorithms. *Journal of Cleaner Production*, 333, 130056.
- Vasanth Raju, N., & Harinarayana, N. S. (2020). Indian Clinical Trials on COVID-19: A Review of Clinical Trials Registry of India (CTRI). Available at SSRN 3674093.

- Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020). Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus. *Journal of Virology*, 94(7) doi:10.1128/JVI.00127-20
- Wang, Y., Zhang, D., Du, G., et al., (2020). Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. *The Lancet*, 395(10236), 1569-1578. doi:10.1016/S0140-6736(20)31022-9
- Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020). Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. *JAMA - Journal of the American Medical Association*, 324(8), 782-793. doi:10.1001/jama.2020.12839
- Wölfel, R., Corman, V. M., Guggemos, W., et al., (2020). Virological assessment of hospitalized patients with COVID-2019. *Nature*, 581(7809), 465-469. doi:10.1038/s41586-020-2196-x
- Wu, C., Chen, X., Cai, Y., et al., (2020). Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Internal Medicine*, 180(7), 934-943. doi:10.1001/jamainternmed.2020.0994
- Wu, F., Zhao, S., Yu, B., et al., (2020). A new coronavirus associated with human respiratory disease in China. *Nature*, 579(7798), 265-269. doi:10.1038/s41586-020-2008-3
- Xu, Z., Shi, L., Wang, Y., et al., (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *The Lancet Respiratory Medicine*, 8(4), 420-422. doi:10.1016/S2213-2600(20)30076-X
- Zhang, L., Lin, D., Sun, X., et al., (2020). Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors. *Science*, 368(6489), 409-412. doi:10.1126/science.abb3405
- Zhou, F., Yu, T., Du, R., et al., (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. *The Lancet*, 395(10229), 1054-1062. doi:10.1016/S0140-6736(20)30566-3
- Zhou, P., Yang, X., Wang, X., et al., (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*, 579(7798), 270-273. doi:10.1038/s41586-020-2012-7
- Zhu, N., Zhang, D., Wang, W., et al., (2020). A novel coronavirus from patients with pneumonia in China, 2019. *New England Journal of Medicine*, 382(8), 727-733. doi:10.1056/NEJMoa2001017